

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/011647 A1**

(51) International Patent Classification<sup>7</sup>: C12N 15/11,  
A61K 31/711

(21) International Application Number:  
PCT/US2003/023104

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/398,605 26 July 2002 (26.07.2002) US

(71) Applicant (for all designated States except US): CHI-  
RON CORPORATION [US/US]; 4560 Horton Street,  
Emeryville, CA 94608 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HAN, Jang  
[US/US]; c/o Chiron Corporation, 4560 Horton Street,  
Emeryville, CA 94608 (US). SEO, Mi Young [US/US];

c/o Chiron Corporation, 4560 Horton Street, Emeryville,  
CA 94608 (US). HOUGHTON, Michael [US/US]; c/o  
Chiron Corporation, 4560 Horton Street, Emeryville, CA  
94608 (US).

(74) Agents: PEET, Richard, C. et al.; Foley & Lardner, Wash-  
ington Harbour, 3000 K Street, N.W., Suite 500, Washing-  
ton, D.C. 20007-5143 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE

The Effect of siRNA<sub>s</sub> on HCV Replication  
In Huh 5-2 Cells



(57) Abstract: The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and method of making modified small interfering RNAs (siRNAs) using human Dicer.

BEST AVAILABLE COPY



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

## Modified Small Interfering RNA Molecules and Methods of Use

### BACKGROUND OF THE INVENTION

The present invention relates to the field of nucleic acid detection and to the phenomenon of RNA silencing, or RNA interference (RNAi). RNA silencing constitutes a phenomenon wherein non-coding RNA molecules mediate specific gene suppression in an organism. In nature, the phenomenon protects an organism's genome from foreign, invading nucleic acids such as transposons, transgenes and viral genes.

The introduction of double-stranded RNA (dsRNA) into a cell triggers RNA silencing, which then degrades endogenous mRNA corresponding to the dsRNA. RNA silencing pathways involve a conversion of dsRNA into short interfering RNAs (siRNAs) that direct ribonucleases to homologous mRNA targets (Baulcombe *et al.*, 2001). An enzyme called Dicer processes the dsRNA into siRNAs, which are 20-25 nucleotides long. The siRNAs then assemble into endoribonuclease-containing complexes known as RNA-induced silencing complexes (RISCs). Subsequently, the siRNAs guide the RISCs to complementary RNA molecules, where the RISCs cleave and destroy the target mRNA. Small amounts of dsRNA can silence a large amount of target mRNA due to an amplification component of RNA silencing (Fire *et al.*, *Nature*, 391:806-811 (1998)).

The first evidence that dsRNA produces efficient gene silencing through RNAi came from studies on the nematode *Caenorhabditis elegans* (Fire *et al.*, *Nature*, 391:806-811 (1998) and U.S. Patent No. 6,506,559). Later studies in the fruit fly *Drosophila melanogaster* demonstrated that RNAi is a multi-step mechanism (Elbashir *et al.*, *Genes Dev.*, 15(2): 188-200 (2001)).

Although dsRNA can mediate gene-specific interference in mammalian cells (Wianny, F. and Zernicka-Goetz, M., *Nature Cell Biol.* 2:70-75 (2000) Svoboda, P. *et al.*, *Development* 17:4147-4156 (2000)), the use of RNAi in mammalian somatic cells is often limited by a triggering of dsRNA-dependent protein kinase (PKR), which inactivates the translation factor eIF2a, causes a generalized suppression of protein synthesis and often times causes apoptosis (Gil, J. and Esteban, M., *Apoptosis* 5:107-114(2000)).

Recently, siRNA of approximately 21 or 22 base pairs in length, corresponding to targeted RNA or DNA sequences, were shown to disrupt the expression of the targeted sequences in mammalian cells (Elbashir, S.M., *et al.*, *Nature* 411: 494-498 (2001)). However, it is not clear that all RNA or DNA sequences of a mammalian cell's genome are susceptible to siRNA. It is also uncertain that every mammalian cell type possesses the necessary machinery for effectuating gene-specific suppression using siRNA. Further, siRNA is of limited use for at least two reasons: (a) the transient nature of the suppression effect seen in cells where the siRNA has been administered, and (b) the necessity for chemical synthesis of siRNAs before their use (Tuschl, T., *Nature Biotech.*, 20: 446-448 (2002)). Also, since siRNAs are unstable *in vivo*, their long-term effectiveness is limited.

An invention that addresses these challenges will improve the utility of RNAi for treating human disease at the level of nucleic acid activity. In particular, such an invention will make RNAi a more practical therapy for viral infections, such as infections with HCV. Current therapies for such viral infections are very limited, and tend to have poor response rates.

## SUMMARY OF THE INVENTION

The present invention provides double-stranded RNA (dsRNA) molecules that mediate RNA interference in target cells. In particular, it provides small interfering RNAs (siRNAs) that inhibit viral replication in infected cells. Preferred dsRNA molecules of the invention correspond to hepatitis C virus (HCV) nucleic acids, and inhibit replication of HCV in hepatic cells.

In another aspect, the invention provides modified dsRNA, including siRNA, molecules that are protected against nuclease degradation, but are able to inhibit viral replication in mammalian cells.

The invention also provides methods of inhibiting viral replication in infected cells by administering dsRNA or siRNA molecules. Modified dsRNA and siRNA molecules are particularly useful in these methods, as they are nuclease resistant, yet retain the biological activity of being able to inhibit viral replication by targeting an RNA sequence in a virus.

The invention further provides a method of making modified siRNAs that target a viral RNA or DNA sequence. The method comprises preparing a dsRNA fragment that contains at least one modified ribonucleotide in at least one strand, and cleaving the dsRNA fragment with Dicer enzyme, resulting in more than one modified siRNA.

Other objects, features and advantages of the invention will become apparent from the following detailed description. The description and specific examples indicate preferred embodiments, but should not be considered limiting, as various modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description. Further, the examples demonstrate the principle of the invention, but cannot be expected to specifically illustrate all useful applications.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 depicts the sequence and secondary structure of the 5' UTR from the HCV genome. It also provides specific sequences of siRNAs for inducing RNAi toward HCV in hepatic cells.

Fig. 2 provides sequences for several HCV-specific siRNAs that are useful for inducing RNAi toward HCV in hepatic cells. Each HCV-specific siRNA is identified by the designation provided in the first column.

Fig. 3 shows the nucleotide sequence of the SARS coronavirus.

Fig. 4 is a schematic representation of the open reading frames of the SARS coronavirus.

Fig. 5 depicts a subgenomic HCV replicon contained in the hepatoma cell line Huh 7, which was used to test the efficacy of siRNA in human liver cells.

Fig. 6 depicts the dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line), that were administered different concentrations of siRNA5. Luciferase activity, which was measured at 1, 2 and 3 days post-transfection, fell with increasing doses of siRNA. The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

Fig. 7 depicts the sequence specificity of siRNA5 for inducing HCV-directed RNAi in Huh-7 liver cells.

Fig. 8 demonstrates that siRNA5 is not toxic to Huh-7 cells. ATPase levels were assayed using an ATPase assay kit available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

Fig. 9 depicts the effects of siRNA5 on HCV replication in 21-5 cells (Huh-7 cells containing full-length HCV), as measured by RNA assay. RNA levels were assayed using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

Fig. 10 demonstrates that siRNA5 does not affect the viability of Huh 5-2 cells. Specifically, mRNA encoding GAPDH, an enzyme essential to glycolysis was measured in Huh 5-2 cells transfected with siRNA5 or GAPDH-specific siRNA. The graph demonstrates that siRNA5 did not affect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

Fig. 11 depicts a dose response of normalized luciferase activity in Huh 7 cells containing a subgenomic HCV replicon (5-2 line) that were administered different concentrations of 2'-fluoro-siRNA (2'-F-GL2), which targets the fruit fly luciferase gene. Luciferase activity, which was measured at 2 days post-transfection, fell with

increasing doses of siRNA. The luciferase assay was performed using a Firefly Luciferase kit (Promega Corp., Madison, WI), according to the manufacturer's instructions.

Fig. 12 demonstrates an inhibition of luciferase activity in 5-2 cells using the siRNA Chol-GL2 in the absence of liposomes.

Fig. 13 depicts an autoradiograph of 5'-labeled siRNA duplexes separated by PAGE, and shows the stability of 2'-fluoro-modified siRNA (2'-F-GL2) incubated in human serum for up to 10 days. The siRNA duplexes were subjected to incubation with human serum and analysis by 20% PAGE. The composition of the lanes is as follows: Lanes 1, 11 and 21: <sup>32</sup>P-end labeled siRNA alone; Lanes 2-10, 12-20 and 22-25: siRNA incubated with human serum. Lanes 2 & 12, 1 min ; Lanes 3 & 13, 5 min ; Lanes 4 & 14, 15 min ; Lanes 5 & 15, 30 min ; Lanes 6 & 16, 1 hr ; Lanes 7 & 17, 2 hr ; Lanes 8 & 18, 4 hr ; Lanes 9 & 19, 8 hr ; Lanes 10 & 20, 24 hr ; Lanes 22, 24 hr ; Lanes 23, 48 hr ; Lanes 24, 120 hr ; Lanes 25, 240 hr incubation, respectively.

Fig. 14 demonstrates the use of recombinant human dicer to convert fluorinated dsRNA into 2'-F-siRNA. The composition of the lanes is as follows: Lane 1: size marker,  $\lambda$ HindIII+ $\phi$ X174/HaeIII; Lane 2: ribo/ribo homoduplex RNA; Lane 3: ribo/2'-F heteroduplex RNA; Lane 4: 2'-F/ribo heteroduplex RNA; Lane 6: size marker, 10bp DNA ladder; Lane 7: ribo/ribo homoduplex siRNA; Lane 8: ribo/2'-F heteroduplex siRNA; Lane 9: 2'-F/ribo heteroduplex siRNA; Lane 10: 2'-F/2'-F homoduplex siRNA.

Fig. 15 shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to HCV-specific siRNAs. Luciferase activity fell with increasing doses of each siRNA.

Fig. 16 shows that cholesterol shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to cholesterol-modified GL2 siRNA.



## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides dsRNA molecules that are about 10 to about 30 nucleotides long, and that mediate RNA interference in target cells. Preferably, the inventive molecules are chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids.

As used herein, "RNA interference" (RNAi) refers to sequence-specific or gene specific suppression of gene expression (protein synthesis) that is mediated by siRNA, without generalized suppression of protein synthesis. While the invention is not limited to a particular theory or mode of action, RNAi may involve degradation of messenger RNA (mRNA) by an RNA-induced silencing complex (RISC), preventing translation of the transcribed mRNA. Alternatively, it may involve methylation of genomic DNA, which shunts transcription of a gene. The suppression of gene expression caused by RNAi may be transient or it may be more stable, even permanent.

"Gene suppression", "targeted suppression", "sequence-specific suppression", "targeted RNAi" and "sequence-specific RNAi" are used interchangeably herein. Furthermore, sequence-specific suppression, as used herein, is determined by separately assaying levels of the protein targeted for suppression in cells containing the siRNA (experimental cells) and in cells not containing the identical siRNA (control cells), then comparing the two values. Experimental and control cells should be derived from the same source and same animal. Also, control and experimental cells used in determining the level or quantity of gene suppression should be assayed under similar, if not identical, conditions.

RNA is a polymer of ribonucleotides, each containing the sugar ribose in association with a phosphate group and a nitrogenous base (typically, adenine, guanine, cytosine, or uracil). Like its cousin, DNA, RNA can form complementary hydrogen bonds. Therefore, RNA may be double-stranded (dsRNA), single-stranded (ssRNA) or double-stranded with a single-stranded overhang. Common types of RNA include messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), micro RNA (miRNA) and small hairpin



RNA (shRNA), each of which plays a specific role in biological cells. As used herein, the term "RNA" includes all of these.

"Small interfering RNA" (siRNA) refers to double-stranded RNA molecules from about 10 to about 30 nucleotides long that are named for their ability to specifically interfere with protein expression. Preferably, siRNA molecules are 12-28 nucleotides long, more preferably 15-25 nucleotides long, still more preferably 19-23 nucleotides long and most preferably 21-23 nucleotides long. Therefore, preferred siRNA molecules are 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 or 29 nucleotides in length.

The length of one strand designates the length of an siRNA molecule. For instance, an siRNA that is described as 21 ribonucleotides long (a 21-mer) could comprise two opposite strands of RNA that anneal together for 19 contiguous base pairings. The two remaining ribonucleotides on each strand would form an "overhang." When an siRNA contains two strands of different lengths, the longer of the strands designates the length of the siRNA. For instance, a dsRNA containing one strand that is 21 nucleotides long and a second strand that is 20 nucleotides long, constitutes a 21-mer.

siRNAs that comprise an overhang are desirable. The overhang may be at the 5' or the 3' end of a strand. Preferably, it is at the 3' end of the RNA strand. The length of an overhang may vary, but preferably is about 1 to about 5 bases, and more preferably is about 2 nucleotides long. Preferably, the siRNA of the present invention will comprise a 3' overhang of about 2 to 4 bases. More preferably, the 3' overhang is 2 ribonucleotides long. Even more preferably, the 2 ribonucleotides comprising the 3' overhang are uridine (U).

siRNAs of the present invention are designed to interact with a target ribonucleotide sequence, meaning they complement a target sequence sufficiently to bind to the target sequence. Preferably the target ribonucleotide sequence derives from a disease producing agent or pathogen. More preferably, the target ribonucleotide sequence is in a virus genome of an RNA virus or a DNA virus. Even more preferably, the virus is selected from the group consisting of hepatitis C virus

(HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.

Hepatitis C virus (HCV) is a highly preferred virus target. Figure 1 and Figure 2 disclose the nucleic acid sequences for several HCV-specific siRNA molecules. Among those shown, siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4 have shown particularly good activity, and therefore are highly preferred. siRNAs at least 80%, 90%, or 95%, identical to these highly preferred siRNAs also constitute part of the invention..

Another preferred virus target is the coronavirus, which is associated with upper respiratory infections in humans and recently has been linked with SARS (severe acute respiratory syndrome). Coronavirus has the largest known RNA virus genome, 32 kilobases long, and its genome is composed of positively stranded RNA. (See Figure 5) Each coronavirus mRNA has a 5'-end leader sequence of 60 to 80 nucleotides that is identical to the 5'-UTR of genomic RNA approximately 200 nucleotides long. (See Figure 6) These sequences are highly conserved, and therefore, provide an excellent source of target sequences for which siRNAs. See Fundamental Virology, 3<sup>rd</sup> Ed., Chapter 18, p. 541-560 (Eds. Fields, Knipe and Howley), Lippincott-Raven (1995). In one embodiment, the entire leader sequence (nucleotides 1-72) is targeted. In another embodiment, one or more sections of the leader sequence is targeted. In a preferred embodiment, nucleotides 64-72 (TAAACGAAC) of the leader sequence are targeted. siRNA targeted to the coronavirus may be modified or unmodified.

In one embodiment, the invention provides an siRNA molecule comprising a ribonucleotide sequence at least 80% identical to a ribonucleotide sequence from a target agent or virus. Preferably, the siRNA molecule is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the ribonucleotide sequence of the target agent or virus. The target can be the entire viral genome, a primary transcript, an open reading frame, or any portion of these. Most preferably, an siRNA will be 100% identical to the nucleotide sequence of a target agent or virus. However, siRNA molecules with insertions, deletions or single point mutations relative to a target may

also be effective. Tools to assist siRNA design are readily available to the public. For example, a computer-based siRNA design tool is available on the internet at [www.dharmacon.com](http://www.dharmacon.com).

By way of example, a polynucleotide having a nucleotide sequence at least 95% "identical" to a reference nucleotide sequence means that the polynucleotide's sequence may include up to five point mutations per 100 nucleotides of the reference nucleotide sequence, or 1 point mutation per 20 nucleotides. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the ribonucleotide sequence of a target agent or virus can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, Madison, WI). Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489 (1981)) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference ribonucleotide sequence and that gaps in homology of up to 5% of the total number of ribonucleotides in the reference sequence are allowed.

The present invention also includes siRNA molecules that have been chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids that may be present in cells. In the

case where a target RNA is virus-specific, the modified siRNAs are able to bind to the virus specific RNAs or DNAs, thereby inactivating the virus.

A modified siRNA of the present invention comprises a modified ribonucleotide, and is resistant to enzymatic degradation, such as RNase degradation, yet retains the ability to inhibit viral replication in a cell containing the specific viral target RNA or DNA sequences. The siRNA may be modified at any position of the molecule so long as the modified siRNA binds to a target sequence and is resistant to enzymatic degradation. Modifications in the siRNA may be in the nucleotide base, *i.e.*, the purine or the pyrimidine, the ribose or the phosphate. Preferably, the modification occurs at the 2' position of at least one ribose in an siRNA.

More specifically, the siRNA is modified in at least one pyrimidine, at least one purine or a combination thereof. However, generally all pyrimidines (cytosine or uracil), or all purines (adenosine or guanine) or a combination of all pyrimidines and all purines of the siRNA are modified. More preferably, the pyrimidines are modified, and these pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. Ribonucleotides on either one or both strands of the siRNA may be modified.

Ribonucleotides containing pyrimidine bases found in RNA (cytidine and uridine) can be chemically modified by adding any molecule that inhibits RNA degradation or breakdown of the base, the ribose or the phosphates. As previously noted, the 2' position of ribose is a preferred site for modification. 2' modified siRNAs have a longer serum half-life and are resistant to degradation, relative to unmodified siRNAs or single-stranded RNAs, such as antisense or ribozyme. 2'-modified pyrimidine ribonucleotides can be formed by a number of different methods known in the art.

A preferable chemical modification is the addition of a molecule from the halide chemical group to a ribonucleotide of siRNA. Within the halides, fluorine is a preferred molecule. Besides fluoro-, other chemical moieties such as methyl-, methoxyethyl- and propyl- may be added as modifications. The most preferred

modification, though, is fluoro-modification, such as a 2'-fluoro-modification or a 2',2'-fluoro-modification.

Thus, in a preferred embodiment of the invention, siRNA is modified by the addition of a fluorine molecule to the 2' carbon of a pyrimidine ribonucleotide. The siRNA may be fluorinated completely or partially. For example, only the cytosine ribonucleotides may be fluorinated. Alternatively, only the uracil ribonucleotides may be fluorinated. In a preferred embodiment, both uracil and cytosine are fluorinated. Only one strand, either sense or antisense, of siRNA may to be fluorinated. Even partial 2' fluorination of siRNA gives protection against nucleolytic degradation. Importantly, 2' fluorinated siRNA is not toxic to cells, an unexpected result given that fluorine chemistry usually is toxic to living organisms.

In addition, modified siRNAs of the present invention may contain chemical modifications that inhibit viral RNA polymerases. For example, siRNAs may comprise one or more nucleosides that inhibit viral RNA-dependent RNA polymerases. Examples of such nucleosides and other chemical modifications exist in WO 02/057425, WO 02/057287, WO 02/18404, WO 02/100415, WO 02/32920, WO 01/90121, US patent No. 6,063,628 and US published application No. 2002/0019363.

siRNA can be prepared in a number of ways, such as by chemical synthesis, T7 polymerase transcription, or by treating long double stranded RNA (dsRNA) prepared by one of the two previous methods with Dicer enzyme. Dicer enzyme creates mixed populations of dsRNA from about 21 to about 23 base pairs in length from dsRNA that is about 500 base pairs to about 1000 base pairs in size. Unexpectedly, Dicer can effectively cleave modified strands of dsRNA, such as 2' fluoro-modified dsRNA. Before development of this method, it was previously thought that Dicer would not be able to cleave modified siRNA. The Dicer method of preparing siRNAs can be performed using a Dicer siRNA Generation Kit available from Gene Therapy Systems (San Diego, CA).

The invention particularly includes a method of making a modified siRNA that targets a nucleic acid sequence in a virus, comprising (a) preparing a modified-double stranded RNA (dsRNA) fragment containing at least one modified

ribonucleotide in at least one strand, and (b) cleaving the modified-dsRNA fragments with recombinant human Dicer, resulting in more than one modified siRNA. The method may further comprise (c) isolating the modified siRNAs.

In the methods for making siRNA, a dsRNA fragment can be prepared by chemical synthesis or in vitro translation. In one embodiment, the modified siRNA is a 2' modified siRNA in which the modification is at the 2' position of at least one ribonucleotide of said siRNA. The modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl and propyl-modification. Preferably the fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification. The pyrimidines, the purines or a combination thereof of the siRNA are modified. More preferably, the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. One or both strands of the siRNA may contain one or more modified ribonucleotide.

The invention further provides a method of inactivating a target agent or virus in a patient by administering to the patient a dsRNA in an effective amount to inactivate the targeted agent or virus. Preferably the dsRNA is modified as described above. RNA interference toward a targeted DNA segment in a cell can be achieved by administering a double-stranded RNA molecule to the cells, wherein the ribonucleotide sequence of the double-stranded RNA molecule corresponds to the ribonucleotide sequence of the targeted DNA segment. Preferably, the dsRNA used to induce targeted RNAi is siRNA.

As used herein "targeted DNA segment" is used to mean a DNA sequence encoding, in whole or in part, an mRNA for a targeted protein, including introns or exons, where suppression is desired. DNA segment can also mean a DNA sequence that normally regulates expression of the targeted protein, including but not limited to the promoter of the targeted protein. Furthermore, the DNA segment may or may not be a part of the cell's genome or it may be extrachromosomal, such as plasmid DNA.

The present invention is particularly directed to a method of inactivating a virus in a patient by administering to the patient an siRNA, preferably a modified siRNA, in an effective amount to inactivate the virus. The siRNA is preferably about



10 to about 30 ribonucleotides in length, more preferably 12-28 ribonucleotides, more preferably 15-25 ribonucleotides, even more preferably 19 –23 ribonucleotides and most preferably 21-23 ribonucleotides.

Also, the method of inactivating a virus preferably utilizes an siRNA that is modified at the 2' position of at least one ribonucleotide of said siRNA. The siRNA may be modified with chemical groups selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-. Fluoro-modification is most preferred, and either a 2'-fluoro-modification or a 2',2'-fluoro-modification is useful in the method. The modification may be at a pyrimidine, a purine or a combination thereof of the siRNA. More preferably the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. In one embodiment, one strand of the siRNA contains at least one modified ribonucleotide, while in another embodiment, both strands of the siRNA contain at least one modified ribonucleotide.

siRNAs useful in treatment methods may also be modified by the attachment of at least one, but preferably more than one, receptor-binding ligand(s) to the siRNA. Such ligands are useful to direct delivery of siRNA to a target virus in a body system, organ, tissue or cells of a patient, such as the liver, gastrointestinal tract, respiratory tract, the cervix or the skin.

In preferred embodiments, receptor-binding ligands are attached to either a 5'-end or a 3'-end of an siRNA molecule. Receptor-binding ligands may be attached to one or more siRNA ends, including any combination of 5'- and 3'-ends. Thus, when receptor binding ligands are attached only to the ends of an siRNA molecule, anywhere between 1 and 4 such ligands may be attached.

The selection of an appropriate ligand for targeting siRNAs to viruses in particular body systems, organs, tissues or cells is considered to be within the ordinary skill of the art. For example, to target an siRNA to hepatocytes, cholesterol may be attached at one or more ends, including any combination of 5'- and 3'-ends, of an siRNA molecule. The resultant cholesterol-siRNA is delivered to hepatocytes in the liver, thereby providing a means to deliver siRNAs to this targeted location. Other



ligands useful for targeting siRNAs to the liver include HBV surface antigen and low-density lipoprotein (LDL).

As another example, siRNA molecules that target Human Immunodeficiency virus type 1 (HIV-1) can be delivered to T lymphocytes where the target nucleic acids are located (Song, E. *et al.*, *J. of Virology*, 77(13): 7174-7181 (2003)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, HIV-1 surface antigen capable of binding to the CD4 surface protein located on T-cells (Kilby, M. *et al.*, *New England J. of Medicine*, 348(22): 2228-38 (2003)).

Similarly, siRNA molecules that target Influenza A virus can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Ge, Q. *et al.*, *Proc. Natl. Acad. of Sciences*, 100(5): 2718-2723 (2002)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, the Influenza virus surface antigen, which is capable of binding to the sialic acid residues located on the surface of the epithelial cells (Ohuchi, M., *et al.*, *J. of Virology*, 76(24): 12405-12413 (2002); Glick, G. *et al.*, *J. of Biol. Chem.*, 266 (35): 23660-23669 (1991)).

Also, siRNA molecules that target respiratory syncytial virus (RSV) can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Bitko, V. *et al.*, *BMC Microbiology*, 1:34 (2001)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, RSV surface antigen (Malhotra, R. *et al.*, *Microbes and Infection*, 5: 123-133 (2003)).

As still another example, siRNAs that target Human Papillomavirus (HPV) can be delivered to basal epithelial cells where the target nucleic acids are located (Hall, A. *et al.*, *J. of Virology*, 77(10): 6066-6069 (2003)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, HPV surface antigen capable of binding to heparin sulfate proteoglycans located on the surface of basal epithelial cells (Bousarghin L. *et al.*, *J. of Virology*, 77(6): 3846-3850 (2002)).

Further, siRNAs that target Poliovirus (PV) can be delivered to cells of the nervous system where the target nucleic acids are located (Gitlin, L. *et al.*, *Nature*,

418: 430-434 (2002)). This delivery can be accomplished by attaching, at the 3' -end or 5' -end of siRNA molecules, PV surface antigen capable of binding to the CD155 receptor located on the surface of neurons (He, Y. *et al.*, *Proc. Natl. Acad. of Sciences*, 97 (1): 79-84 (2000)).

As noted, the methods of treatment are intended to target disease-causing agents or pathogens, and more particularly viruses, which can be either RNA viruses or DNA viruses. Preferred viruses are selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus. More preferably the target virus is hepatitis C virus or a coronavirus.

In one aspect, the method utilizes an siRNA prepared by (a) identifying a target ribonucleotide sequence in a virus genome for designing a small interfering RNA (siRNA) and (b) producing a siRNA that has been modified to contain at least one modified ribonucleotide. Preferably, the siRNA comprises a double-stranded RNA molecule with a first strand ribonucleotide sequence corresponding to a ribonucleotide sequence corresponding to a target ribonucleotide sequence in the virus, and a second strand comprising a ribonucleotide sequence complementary to the target ribonucleotide sequence. The first and second strands should be separate complementary strands that hybridize to each other to form a double-stranded RNA molecule. Moreover, one or both of the strands should comprise at least one modified ribonucleotide.

In preferred embodiments of the invention, the siRNA targets a ribonucleotide sequence in the hepatitis C virus genome. The target ribonucleotide sequence comprises a conserved ribonucleotide sequence necessary for HCV replication, and the conserved ribonucleotide sequence is selected from the group consisting of 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), core, and NS3 helicase. Highly preferred siRNA molecules comprise a sequence at least 80% identical to those of siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, or siRNA5B4. The siRNAs may be unmodified, or modified as described above.

Methods of inhibiting the replication of HCV in cells positive for HCV should not be toxic to the cells, or cause apoptosis in the treated cells. Preferably, the inhibition of HCV replication is specifically tailored to affect only HCV replication in the cells, such that normal growth, division or metabolism is not affected. Cells in which HCV has been shown to replicate include, but are not limited to hepatic cells, B cell lymphocytes and T cell lymphocytes. Preferably, a method of inhibiting the replication of HCV is performed in hepatic cells.

According to the invention, "hepatic cells" can be from any animal source. Further, the hepatic cells may be in cell culture, or part of a tissue, or an organ, in part or in whole. The phrase hepatic cells is meant to include any cell constituting a normal, abnormal or diseased liver cell. Examples of hepatic cells include, but are not limited to, Kupffer cells, hepatocytes and cells comprising a hepatocellular carcinoma. "Hepatic cells" is not meant to include cells that make up discrete structures within the liver, such as endothelial cells lining blood vessels. A tissue or organ containing the hepatic cells may be within a subject or may be biopsied or removed from the animal. Additionally, the tissue may be "fresh" in that the tissue would be recently removed from a subject, without any preservation steps between the excision and the methods of the current invention. Prior to application of the methods of the current invention, the tissue may also have been preserved by such standard tissue preparation techniques including, but not limited to, freezing, quick freezing, paraffin embedding and tissue fixation. Furthermore, the tissue may also be a xenograft or a syngraft on or in another host animal. As used herein, the terms animal and subject are used interchangeably.

According to the invention, "hepatitis C virus," or "HCV," takes its ordinary meaning in the art as of the date of invention. The hepatitis C virus is an RNA virus of the *Flaviviridae* family. For example as used herein, HCV includes, but is not limited to genotypes 1-11 (using the most common genotyping system), with these genotypes being broken down into sub-types, some of which include but are not limited to 1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 4a, 4b, 4c, 4d, 4e, 5a, 6a, 7a, 7b, 8a, 8b, 9a, 10a and 11a. Further, isolates from individuals consist of closely related yet heterogeneous populations of viral genomes, sometimes referred to as quasispecies.

Pestivirus is yet another target of the present invention. As used herein, "pestivirus" takes its ordinary meaning in the art as of the date of invention. The pestivirus belongs to the family *Flaviviridae*. Pestivirus is widespread throughout the Australian cattle population. It is believed that about 70% of herds are actively infected with pestivirus. Infection of susceptible animals can cause a variety of diseases - some not apparent until well after the initial spread of the virus into a herd. Pestivirus is a genus of viruses that includes hog cholera virus, bovine viral diarrhea virus (BVDV) and border disease virus (BDV) or hairy-shaker disease virus.

siRNA may be administered to a patient by intravenous injection, subcutaneous injection, oral delivery, liposome delivery or intranasal delivery. The siRNA may then accumulate in a target body system, organ, tissue or cell type of the patient.

The present invention also provides a method of inhibiting the replication of a virus in mammalian cells, comprising transfecting cells harboring the virus with a vector that directs the expression of virus-specific siRNA. In one embodiment, the invention provides a method of inhibiting the replication of hepatitis C virus (HCV) in cells positive for HCV, comprising transfecting HCV-positive cells with a vector that directs the expression of an HCV-specific siRNA. The cells may be evaluated to determine if a marker in the cells has been inhibited by the siRNA.

Thus, the invention also provides vectors and host cells comprising a nucleic acid segment encoding the described siRNAs.

Vectors of the present invention may be employed for producing siRNAs by recombinant techniques. Thus, for example, a DNA segment encoding an siRNA may be included in any one of a variety of expression vectors for expressing any DNA sequence. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in a desired host.

The appropriate DNA segment may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA segment in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct siRNA synthesis. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma Virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter. Preferably the promoters of the present invention are from the type III class of RNA polymerase III promoters. More preferably, the promoters are selected from the group consisting of the U6 and H1 promoters. The U6 and H1 promoters are both members of the type III class of RNA polymerase III promoters. The promoters of the present invention may also be inducible, in that expression may be turned "on" or "off." For example, a tetracycline-regulatable system employing the U6 promoter may be used to control the production of siRNA. The expression vector may or may not contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or tetracycline or ampicillin resistance.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK),  $\alpha$ -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader

sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

In one embodiment, the invention provides a vector, wherein the DNA segment encoding the sense strand of the RNA polynucleotide is operably linked to a first promoter and where the DNA segment encoding the antisense (opposite) strand of the RNA polynucleotide molecule is operably linked to a second promoter. In other words, each strand of the RNA polynucleotide is independently expressed. Furthermore, the promoter driving expression of each strand can be identical or each one may be different from the other promoter.

In another embodiment, the vector of the current invention may comprise opposing promoters. For example, the vector may comprise two U6 promoters on either side of the DNA segment encoding the sense strand of the RNA polynucleotide and placed in opposing orientations, with or without a transcription terminator placed between the two opposing promoters. The U6 opposing promoter construct is similar to the T7 opposing promoter construct as described in Wang, Z. *et al.*, J. Biol. Chem. 275: 40174-40179 (2000). See Miyagishi, M. and Taira, K., Nature Biotech. 20: 497-500 (2002).

In another embodiment, the DNA segments encoding both strands of the RNA polynucleotide are under the control of a single promoter. In one embodiment, the DNA segments encoding each strand are arranged on the vector with a "loop" region interspersed between the two DNA segments, where transcription of the DNA segments and loop region creates one RNA transcript. The single transcript will, in turn, anneal to itself creating a "hairpin" RNA structure capable of inducing RNAi. The "loop" of the hairpin structure is preferably from about 4 to about 6 nucleotides in length. More preferably, the loop is 4 nucleotides in length.

The vector containing the appropriate DNA sequence as described herein, as well as an appropriate promoter or control sequence, may be employed to transform



an appropriate host to permit the host to express the siRNA. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y. (1989), the disclosure of which is hereby incorporated by reference.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, cloning vectors or expression vectors. The vectors may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells may be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. A host cell may be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell may be a prokaryotic cell, such as a bacterial cell. Preferably, host cells are mammalian cells. More preferably, host cells are hepatic cells. Introduction of a construct into host cells can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., et al., *Basic Methods in Molecular Biology* (1986)).

The term patient, as used herein, refers to an animal, preferably a mammal. More preferably the patient can be a primate, including non-human and humans. The terms subject and patient are used interchangeably herein.

The treatments envisioned by the current invention can be used for subjects with a pre-existing viral infection, or for subjects pre-disposed to an infection. Additionally, the methods of the current invention can be used to correct or compensate for cellular or physiological abnormalities involved in conferring susceptibility to viral infections in patients, and/or to alleviate symptoms of a viral infections in patients, or as a preventative measure in patients.



The method of treating a patient having a viral infection involves administration of compositions to the subjects. As used herein, composition can mean a pure compound, agent or substance or a mixture of two or more compounds, agents or substances. As used herein, the term agent, substance or compound is intended to mean a protein, nucleic acid, carbohydrate, lipid, polymer or a small molecule, such as a drug.

In one embodiment of the current invention, the composition administered to the subject is a pharmaceutical composition. Further, the pharmaceutical composition can be administered orally, nasally, parenterally, intrasystemically, intraperitoneally, topically (as by drops or transdermal patch), buccally, or as an oral or nasal spray. Intranasal delivery of a virus that causes upper respiratory diseases, such as the coronavirus or the metapneumovirus, would be a particularly advantageous delivery mode. The term "parenteral," as used herein, refers to modes of administration that include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. The pharmaceutical compositions as contemplated by the current invention may also include a pharmaceutically acceptable carrier.

"Pharmaceutically acceptable carrier" includes, but is not limited to, a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type, such as liposomes.

A pharmaceutical composition of the present invention for parenteral injection can comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the present invention can also contain adjuvants such as, but not limited to, preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorb acid, and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, to prolong the effect of the drugs, it is desirable to slow the absorption from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, can depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compounds are mixed with at least one item pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders

such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form can also comprise buffering agents.

Solid compositions of a similar type can also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms can contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive,

castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, can contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Alternatively, the composition can be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition is preferably such that the active ingredients do not dissolve therein to any substantial extent. The pressurized composition can also contain a surface active agent. The surface active agent can be a liquid or solid non-ionic surface active agent or can be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

The compositions of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compounds of the invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (*see, for example, Prescott, Ed., Meth. Cell Biol. 14:33 et seq (1976)*).

One of ordinary skill in the art will appreciate that effective amounts of the agents of the invention can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. A "therapeutically effective" amount of the inventive compositions can be

determined by prevention or amelioration of adverse conditions or symptoms of diseases, injuries or disorders being treated. The agents can be administered to a subject, in need of treatment of viral infection, as pharmaceutical compositions in combination with one or more pharmaceutically acceptable excipients. It will be understood that, when administered to a human patient, the total daily usage of the agents or composition of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the agents at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.

Dosing also can be arranged in a patient specific manner to provide a predetermined concentration of the agents in the blood, as determined by techniques accepted and routine in the art. Thus patient dosaging can be adjusted to achieve regular on-going blood levels, as measured by HPLC, on the order of from 50 to 1000 ng/ml.

It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein can be made without departing from the scope of the invention or any embodiment thereof.

### EXAMPLES

The examples demonstrate that siRNA, including modified siRNA, can effectively inhibit viral replication in mammalian cells. Moreover, the examples

show that the inventive siRNAs promote HCV RNA degradation in human liver cells and establish that hepatocytes possess the necessary functional components of modified siRNA-induced silencing. The examples also demonstrate that siRNA technology can be used as a therapy to inhibit HCV replication in host cells. The inventors, by submitting the following examples, do not intend to limit the scope of the claimed invention.

### EXAMPLE 1

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol, 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication (Fig. 5). Owing to cell culture adaptive mutations introduced into the genome (Bart), these 5-2 cells replicate HCV RNA at levels of up to  $5 \times 10^4$  virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made (Fig 5). Briefly, 2 oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the antisense direction were generated. Each oligo DNA was then transcribed *in vitro* to produce (+) and (-) RNA and then treated with DNAase I to remove the DNA template. The two RNA strands were allowed to anneal at 37°C overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove unreacted ssRNA species, the dsRNA was purified for transfection.

Several other siRNA duplexes were designed, including GL2 and GL3, that were directed against the fruit fly and sea pansy luciferase genes, respectively. Using standard transfection techniques, the siRNAs were transfected into the 5-2 cells and luciferase activity was measured to determine the effect of the siRNAs on HCV replication. Luciferase activity was measured 48 hours after transfection. In cells



where siRNA5 was transfected, there was reduced luciferase activity of up to 85%, in a dose responsive manner (Fig. 6). The inhibition of luciferase activity was not seen in cells that were transfected with irrelevant siRNA (SIN). The sequence of SIN was taken from sindbis virus transcription promoter (Fig. 1).

## EXAMPLE 2

The sequence specificity of the siRNA5 response was further tested using additional siRNA duplexes, GL2 and GL3. Figure 1 shows that GL2 and GL3 differ from each other by 3-nucleotides. Luciferase activity was reduced by 90% in cells transfected with siRNA5 or GL2, but no significant reduction was seen in cells transfected with GL3 (Fig. 7). The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

## EXAMPLE 3

Whether or not siRNA5 was toxic to transfected cells also was tested. Toxicity was by measured using an ATPase activity assay. Figure 8 shows that the siRNA5-induced reduction in HCV replication, as seen in Figure 6, was not due to cellular toxicity which is attributed to non sequence-specific RNAi. ATPase levels were assayed using an ATPase assay kit from Promega (Madison, WI) according to the manufacturer's instructions.

## EXAMPLE 4

The full-length HCV replicon may possess the ability to adapt and suppress RNAi, thus replicating in spite of the presence of siRNA, as documented in Li, H, Science 296:1319-1321 (2002). To determine the effects of siRNA5 on replication of full-length HCV RNA in Huh-7 cells, from the 21-5 cell line, harboring the selectable full-length HCV replicon, were treated with siRNA5. Levels of HCV RNA were measured by quantitative PCR using TaqMan™ (F. Hoffman La-Roche, Switzerland). The results as seen in Figure 9 show that siRNA-directed silencing reduced steady-



state viral RNA production, even in the setting of an adapted HCV mutant, where RNA replication was very high. Results from both subgenomic and full-length HCV replicons suggest that none of the HCV proteins can suppress RNA interference.

### EXAMPLE 5

Whether or not siRNA5 was toxic to transfected cells also was tested. Specifically, mRNA encoding GAPDH, an enzyme essential in glycolysis, was measured in Huh 5-2 cells transfected with siRNA5, or siRNA specific towards the GAPDH sequence. Figure 10 demonstrates that siRNA5 did not affect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland) according to the manufacturer's instructions.

### EXAMPLE 6

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to replicate in an infected liver, portions of HCV-infected human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the HCV-infected liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days.

At the end of the dosing regimen the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

### EXAMPLE 7

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to infect a healthy liver, portions of normal human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the healthy liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days. After the pre-dosing regimen, active HCV is then injected intravenously, or via hepatic injection, into the mice.

At about 6, 12, 18, 24 hours, and periodically up to about 5 days after the mice are infected with HCV, the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

### EXAMPLE 8

Modified siRNA can be prepared by chemical synthesis. In one embodiment, each C and U within a siRNA duplex, *e.g.* GL2, can be substituted with 2'-F-U and 2'-F-C. To produce siRNA with 3'-end overhangs comprising 2'-F-U and 2'-F-C, a universal support can be used. By selectively cleaving the oligo from the support, a practitioner can ensure that residues of the overhangs comprise modified nucleotides. Alternatively, the nucleotides comprising the 3'-end overhang can be unmodified dTdT.

2'-F RNA oligonucleotides can be synthesized on an Applied Biosystems 8909 or 8905 DNA/RNA synthesizer using the standard 1  $\mu$ mol beta-cyanoethyl phosphoramidite RNA chemistry protocol. The RNA phosphoramidite monomers and columns of Pac-A, 2'-F-Ac-C, iPr-Pac-G, 2'-F-U, and U-RNA CPG can be obtained from Glen Research (Sterling, VA). (See catalog nos. 10-3000-05, 10-3415-02, 10-3021-05, 10-3430-02, and 20-3430-41E, respectively.) Glen Research's Sulfurizing Reagent (catalog no. 40-4036-10) can be used as an oxidant to obtain a single phosphorothioate backbone between the 3' CPG and a subsequent base. To attain the coupling, the oxidizing step of the standard RNA 1  $\mu$ mol protocol can be replaced with the standard thioate 1  $\mu$ mol protocol. Cholesteryl-TEG phosphoramidite (Glen Research, catalog no. 10-1975-90) and cholesteryl-TEG CPG (Glen Research, catalog no. 20-2975-41E) can be incorporated onto the 5' or 3' ends of one or more of the oligoribonucleotides. After synthesis, the 2'-F RNA's are cleaved and deprotected with 1:1 ammonium hydroxide/methylamine, and the silyl groups are removed with triethylamine trihydrofluoride using standard protocols. See e.g. [http://www.glenres.com/productfiles/technical/tb\\_madeptection.pdf](http://www.glenres.com/productfiles/technical/tb_madeptection.pdf). The oligoribonucleotides are then desalted on Sephadex G25 columns (Pharmacia NAP 25, catalog no. 17-08252-02) with sterilized water and purified using standard gel electrophoresis protocols. Modified siRNAs also can be obtained from commercial vendors such as Dharmacon (Lafayette, CO).

Alternatively, modified siRNA can be prepared by transcription using the Durascribe™ T7 Transcription Kit purchased from Epicentre Technologies (Madison, WI).

The modified siRNAs (dsRNAs) made by these methods contain phosphodiester linked oligonucleotides. Standard methods for making modified single-stranded RNAs, such as antisense molecules, are useful for making modified siRNAs, as modified single-stranded RNAs can be annealed together to form double stranded RNAs. Such standard methods include, but are not limited to, those described in Chiang *et al.*, *J.Biol.Chem.* 266, 18162-18171 (1991); Baker *et al.*, *J.Biol.Chem.* 272, 11994-12000 (1997); Kawasaki *et al.*, *J.Med.Chem.* 36, 831-841 (1993); Monia *et al.*, *J.Biol.Chem.* 268, 14514-14522 (1993).

### EXAMPLE 9

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol, 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication. Owing to cell culture adaptive mutations introduced into the genome, 5-2 cells replicate HCV RNA at levels of up to  $5 \times 10^4$  virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made. Briefly, two oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the antisense direction were generated. Each oligo DNA was then transcribed *in vitro* to produce (+) and (-) RNA and then treated with DNAase I to remove the DNA template. The two RNA strands were allowed to anneal at 37°C overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove the unreacted ssRNA species, the dsRNA was purified for transfection.

Two exemplary modified siRNAs are provided below:

**Chol-GL2**      **Chol-CGUACGCGGAUACUUCGAUU**  
                          **UUGCAUGCGCCUUAUGAAGCU**

GL2 CGUACGCGGAUACUUGGAUU  
UUGCAUGCGCCUUAUGAAGCU

Each C and U within siRNA GL2, directed against the fruit fly luciferase gene, was substituted with 2'-F-U and 2'-F-C. The modified siRNAs were transfected into the 5-2 cells using standard liposome transfection techniques. Specifically, the modified siRNAs were incubated for 4 hrs at 37°C in a 250 µl cell suspension containing 0.5 µl of Oligofectamine (Invitrogen, Carlsbad, CA), for 20 hrs in 375 µl serum containing culture medium, and for 24 hrs at 37°C in fresh medium without the

liposome-siRNA complex. Luciferase activity was measured 48 hours after transfection to determine the effect of the modified siRNAs on HCV replication.

Figure 11 shows that GL2 reduced the luciferase activity at increasing concentrations. Luciferase activity was reduced by 90% in cells transfected with 2'-F-GL2, but no significant reduction was seen in mocked transfected cells or with a control (2'-F-GFP=green fluorescent protein). The luciferase assay was carried out using a Luciferase assay system available from Promega Corp. (Madison, WI), according to the manufacturer's instructions.

The siRNA Chol-GL2 comprises a cholesteryl group on one of the 5' ends. 5-2 cells were incubated with various concentrations of Chol-GL2 in the absence of liposomes. Cells were harvested 48 hours after incubation and assayed for luciferase activity. Figure 12 shows that Chol-GL2 inhibited luciferase gene activity in a dose-dependent manner. InvA refers to chol-GL2 in inverted sequence.

### EXAMPLE 10

To test the stability of 2' chemically modified siRNA compared to unmodified siRNA (siRNA), the following experiment is performed. Four nanograms of siRNA are added to a 20  $\mu$ L volume of 80% human serum from a healthy donor. This mixture is incubated at 37 C° for various times ranging from 1 minute up to 10 days. The results are depicted in lanes 2-10 of Figure 13. The same process is performed for 2' fluorine modified siRNA (2'-F siRNA) as well and the results are shown in lanes 12-20 and 22-25 of Figure 3. When the incubation process is finished, the mixtures are placed on ice and then immediately separated by PAGE along with a <sup>32</sup>P-siRNA control (See Lanes 1, 11 and 21 of Figure 13). The data show that the 2'-modified siRNA is stable over a period of 10 days as compared to unmodified siRNA.

### EXAMPLE 11

To demonstrate the production of modified siRNA from long dsRNA, five micrograms of 1000 bp-long fluorinated dsRNAs (Figure 14, panel (A)) were incubated overnight with 15 units of human Dicer at 37°C. The resulting diced-

siRNAs were purified using a Sephadex G-25 column and electrophoresed on 20% PAGE (Figure 14, panel (B)). Figure 4 shows that recombinant human dicer effectively converts fluorinated-dsRNA into 2'F-siRNA.

## EXAMPLE 12

To further test whether siRNAs directed to the HCV genome confer intracellular immunity against this human pathogen, the assay described in Example 1 was employed to test siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4, each of which is shown in Figure 2. Each siRNA was tested at concentrations of 1 nM, 10nM and 100 nM. As shown in Figure 15, each of the siRNAs significantly inhibited luciferase activity in a dose-dependent manner. SiRNAC2 exhibited particular effectiveness.

## EXAMPLE 13

As a follow-up to the experiments reported in Example 9, assays were performed to demonstrate that the cholesterol modification, and not the fluoro modification directed siRNA molecules to Huh-7 liver cells. Huh-7 cells were incubated with various concentrations of two kinds of Chol-GL2 siRNAs: one having a 2'-fluoro modification and the other lacking such a modification. The results, shown in Figure 16 demonstrate that the deliver of cholesterol-modified siRNA molecules to liver cells is due to the cholesterol, and not other modifications.

## WHAT IS CLAIMED IS:

1. A method for inactivating a virus in a patient, comprising administering to said patient a modified siRNA in an effective amount to inactivate said virus.
2. The method of claim 1, wherein said modified siRNA is a 2' modified siRNA.
3. The method of claim 2, wherein the modification is at the 2' position of at least one ribonucleotide of said siRNA.
4. The method of claim 1, 2 or 3, wherein said modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.
5. The method of claim 4, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification.
6. The method of any one of claims 1-5, wherein pyrimidines of said siRNA are modified, and said pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof.
7. The method of any one of claims 1-6, wherein both strands of said siRNA contain at least one modified nucleotide.
8. The method of any one of claims 1-7, wherein said virus is selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.
9. The method of any one of claims 1-8, wherein said virus is hepatitis C virus.



10. The method of any one of claims 1-9, wherein said siRNA is prepared by
  - (a) identifying a target nucleotide sequence in an HCV genome for designing a small interfering RNA (siRNA); and
  - (b) producing an siRNA that has been modified to contain at least one modified nucleotide.
11. The method of any one of claims 1-9, wherein said siRNA is prepared by
  - (a) identifying a target nucleotide sequence in a virus genome for designing a small interfering RNA (siRNA); and
  - (b) producing an siRNA that has been modified to contain at least one modified nucleotide.
12. The method of claim 10, wherein said target nucleotide sequence is selected from the group consisting of 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), core, and NS3 helicase.
13. The method of any one of claims 1-12, wherein said siRNA is siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2 or siRNA5B4.
14. An siRNA comprising a modified ribonucleotide, wherein said siRNA is resistant to RNase and retains the ability to inhibit viral replication.
15. The siRNA of claim 14, wherein said modified siRNA is a 2' modified siRNA.
16. The siRNA of claim 15, wherein the modification is at the 2' position of at least one ribonucleotide of said siRNA.

17. The siRNA of any one of claims 14-16, wherein the modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.
18. The siRNA of claim 17, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification.
19. The method of any one of claims 14-18, wherein pyrimidines of said siRNA are modified, and said pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof.
20. The siRNA of any one of claims 14-19, wherein both strands of the siRNA contains modified nucleotides.
21. The siRNA of any one of claims 14-20, wherein said siRNA interacts with a target nucleotide sequence in a virus genome.
22. The siRNA of claim 21, wherein said virus is selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.
23. The siRNA of claim 22, wherein said virus is hepatitis C virus (HCV).
24. A method of making a modified siRNA that targets a nucleic acid sequence in a virus comprising:
- (a) preparing a modified-double stranded RNA (dsRNA) fragment containing at least one modified ribonucleotide in at least one strand that spans the genome of a target agent; and

(b) cleaving said modified-dsRNA fragments with recombinant human Dicer resulting in more than one modified siRNA.

25. The method of claim 24, further comprising:

(c) isolating said modified siRNAs.

26. The method of claim 24 or 25, wherein said target agent is a virus.

27. The method of claim 26, wherein said virus is selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.

28. A method for inactivating a virus in a patient comprising administering to said patient a modified siRNA consisting of about 10 to about 30 ribonucleotides in an effective amount to inactivate said virus.

29. The method of claim 28, wherein said modified siRNA consists of about 19 to about 23 ribonucleotides.

30. The method of claim 28 or 29, wherein said modified siRNA is a 2' modified siRNA.

31. The method of any one of claims 28-30, wherein the modification is at the 2' position of at least one ribonucleotide of said siRNA.

32. The method of any one of claims 28-31, wherein said modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.

33. The method of claim 32, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification.
34. The method of any one of claims 28-33, wherein pyrimidines of said siRNA are modified and said pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof.
35. The method of any one of claims 28-34, wherein both strands of said siRNA contain modified nucleotides.
36. The method of any one of claims 28-35, wherein said virus is selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.
37. The method of any one of claims 28-36, wherein said virus is hepatitis C virus (HCV).
38. The method of any one of claims 28-37, wherein said siRNA is prepared by
- (a) identifying a target nucleotide sequence in a HCV genome for designing a small interfering RNA (siRNA); and
  - (b) producing an siRNA that has been modified to contain at least one modified nucleotide.
39. The method of any one of claims 28-37, wherein said siRNA is prepared by
- (a) identifying a target nucleotide sequence in a virus genome for designing a small interfering RNA (siRNA); and

(b) producing an siRNA that has been modified to contain at least one modified nucleotide.

40. The method of claim 38, wherein said target nucleotide sequence comprises a conserved nucleotide sequence necessary for HCV replication.

41. The method of claim 40, wherein said conserved nucleotide sequence is selected from the group consisting of 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), core, and NS3 helicase.

42. The method of any one of claims 28-41, wherein said siRNA is siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2 or siRNA5B4.

43. A double-stranded RNA molecule of from about 10 to about 30 nucleotides that inhibits replication of hepatitis C virus (HCV).

44. The double-stranded RNA molecule of claim 43 comprising a nucleotide sequence at least 80% identical to the nucleotide sequence of siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2 or siRNA5B4.

45. A method of inducing targeted RNA interference toward HCV in hepatic cells, comprising administering the double-stranded RNA molecule of claim 43 or 44 to hepatic cells, wherein the nucleotide sequence of said double-stranded RNA molecule corresponds to an HCV nucleotide sequence.

46. A method of inhibiting replication of hepatitis C virus (HCV), comprising administering the RNA polynucleotide molecule of claim 43 or 44 to cells infected with HCV.

47. A vector comprising a DNA segment encoding the RNA molecule of claim 43 or 44.

48. The vector of claim 47, wherein the sense strand of said double-stranded RNA molecule is operably linked to a first promoter and wherein the antisense strand of said double-stranded RNA molecule of is operably linked to a second promoter.

49. The vector of claim 48, wherein said first and second promoters are selected from the group consisting of U6 and H1.

50. The vector of claim 48 or 49 wherein said first and second promoters are the same.

51. The vector of claim 47, wherein the sense and antisense strands of said RNA molecule are under the control of a single promoter.

52. The vector of claim 51, wherein said single promoter is selected from the group consisting of U6 and H1.

53. A host cell comprising the vector of any one of claims 47-52.

54. A method of inhibiting replication of hepatitis C virus (HCV) in cells carrying HCV, comprising transfecting said cells with the vector of any one of claims 47-52.

55. A method of treating hepatitis C in a subject in need thereof, comprising administering a composition comprising the RNA molecule of claim 43 or 44 to said subject.

56. A method of treating hepatitis C in a subject in need thereof, comprising administering the vector of any one of claims 47-52 to said subject.



57. A modified siRNA molecule, comprising a double-stranded RNA molecule of from about 10 to about 30 nucleotides in length, which mediates RNA interference toward a target agent or virus, and which is linked to at least one receptor-binding ligand.

58. The modified siRNA molecule of claim 57, wherein said receptor-binding ligand is attached to a 5' -end or 3' -end of said siRNA molecule.

59. The modified siRNA molecule of claim 57 or 58, wherein said receptor binding ligand is attached to multiple ends of said siRNA molecule.

60. The modified siRNA molecule of any one of claims 57-59, wherein said receptor-binding ligand is selected from the group consisting of a cholesterol, an HBV surface antigen, low-density lipoprotein, an HIV-1 surface antigen, an influenza virus surface antigen, an RSV surface antigen, an HPV surface antigen and a polio virus surface antigen.

61. The modified siRNA molecule of any one of claims 57-60, wherein said receptor-binding ligand is cholesterol.

62. The modified siRNA molecule of any one of claims 57-61, further comprising a modification at the 2' position of at least one ribonucleotide, which modification at the 2' position of at least one ribonucleotide renders said siRNA resistant to degradation.


63. The modified siRNA molecule of claim 62, wherein said modification at the 2' position of at least one ribonucleotide is a 2'-fluoro-modification or a 2',2'-fluoro-modification.

64. A method of inducing targeted RNA interference in a patient, comprising administering to said patient an effective amount of the siRNA of any one of claims 57-63.

65. A method of inducing targeted RNA interference in a patient, comprising administering to said patient an effective amount of the siRNA of claim 61.

66. A method of inducing targeted RNA interference in a patient, comprising administering to said patient an effective amount of the siRNA of claim 63.

Fig. 1. The Sequence and Secondary Structure of 5'UTR of HCV Genome.



The region where siRNAs was designed is boxed.  
The sequence of the 21-bp siRNA<sub>5</sub> is shown below.

	286	304
siRNA <sub>5</sub>	5'-GUACUGCCUGAUAGGGUGCUU UUCAUGACGGACUAUCCCACG-5'	
GL2	5'-CGUACGCGGAUACUUCGAUU UUGCAUGCGCCUUAUGAAGCU-5'	
GL3	5'-CUUACGCUGAGUACUUCGAUU UUGAAUGCGACUCAUGAAGCU--5'	
SIN	5'-AUCUCUACGGUGGUCCUAAUU UUUAGAGAUGCCACCAGGAUU-5'	

2/24  
Fig. 2

	Domain	sequence (NN-N19-NN)	Position		
5U8	5'UTR	cc-CUGUGAGGAACUACUGUCU-uc	45-63	sense	CUGUGAGGAACUACUGUCUUC
				antisense	AGACAGUAGUCCUCACAGGG
5U9		ua-CUGUCUUCACGCAGAAAGC-gu	58-76	sense	CUGUCUUCACGCAGAAAGCGU
				antisense	GCUUUCUGCGUGAAGACAGUA
5U10		cg-AGACUGCUAGCCGAGUAGU-gu	244-262	sense	AGACUGCUAGCCGAGUAGUGU
				antisense	ACUACUCGGCUAGCAGUCUCG
C1	Core	ga-AUCCUAAACCUCAAAGAAA-aa	352-370	sense	AUCCUAAACCUCAAAGAAAA
				antisense	UUUCUUUGAGGUUUAGGAUUC
C2		gg-UCAGAUCGUCGGUGGAGUU-ua	425-443	sense	UCAGAUCGUCGGUGGAGUUUA
				antisense	AACUCCACCGACGAUCUGACC
C3		gg-UAAGGUCAUCGAUACCCUC-ac	701-719	sense	UAAGGUCAUCGAUACCCUCAC
				antisense	GAGGGUAUCGAUGACCUUACC
C4		ac-GGCGUGAACUAUGCAACAG-gg	822-840	sense	GGCGUGAACUAUGCAACAGGG
				antisense	CUGUUGCAUAGUUCACGCCGU
C5		cc-GGUUGCUCUUUUCUAUCU-uc	852-870	sense	GGUUGCUCUUUUCUAUCUUC
				antisense	AGAUAGAAAAGGAGCAACCGG
5B1	NS5B	gc-UCUUCAUACGGAUCCAUA-ac	8163-8181	sense	UCUUCAUACGGAUCCAUAUC
				antisense	AUUGGAAUCCGUAGAAGAGC
5B2		ca-UACGGAUCCAUAUCUCUC-cu	8167-8187	sense	UACGGAUCCAUAUCUCUCCU
				antisense	GAGAGUAUUGGAAUCCGU AUG
5B3		uu-UGACUCAACGGUCACUGAG-aa	8270-8288	sense	UGACUCAACGGUCACUGAGAA
				antisense	CUCAGUGACCGUUGAGUCAA
5B4		cc-UUCACGGAGGCUAUGACUA-ga	8613-8631	sense	UUCACGGAGGCUAUGACUAGA
				antisense	UAGUCAUAGCCUCCGUGAAGG
5B5		au-ACGACUUGGAGUUGAUAAU-au	8671-8689	sense	ACGACUUGGAGUUGAUAAU
				antisense	GUUAUCAACUCCAAGUCGU AU
5B6		au-UCCUGGCUAGGCAACAUA-uc	8817-8835	sense	UCCUGGCUAGGCAACAUAUC
				antisense	UGAUGUUGCCUAGCCAGGAU
5B7		uu-GUGGCAAGUACCUCUCAA-cu	9160-9178	sense	GUGGCAAGUACCUCUCAA CU
				antisense	UUGAAGAGGUACUUGCCACAA
5B8		au-GUGGUGCCUACUCCUACUU-uc	9317-9335	sense	GUGGUGCCUACUCCUACUUUC
				antisense	AAGUAGGAGUAGGCACCACAU
3U1	3'UTR	cu-UUGGUGGCUCCAUCUAGC-cc	9506-9524	sense	UUGGUGGCUCCAUCUAGCCC
				antisense	GCUAAGAUGGAGCCACCAAAG
3U2		gu-CACGGCUAGCUGUGAAAGG-uc	9531-9549	sense	CACGGCUAGCUGUGAAAGGUC
				antisense	CCUUUCACAGCUAGCCGUGAC
3U3		ag-CCGCUUGACUGCAGAGAGU-gc	9558-9576	sense	CCGCUUGACUGCAGAGAGUGC
				antisense	ACUCUCUGCAGUCAAGCGGCU

Fig. 3

1 ttattaggt ttacctacc caggaaaagc caaccaacct cgatctctg tagatctgt  
 61 ctctaaacga actttaaact ctgtgtagct gtcgctcggc tgcagccta gtgcacctac  
 121 gcagtataaa caataataaa ttctactgtc gttgacaaga aacgagtaac tcgtccctct  
 181 tctgcagact gcttacgggt tcgtccgtgt tgcagtcgat catcagcata cctaggtttc  
 241 gtccgggtgt gaccgaaagg taagatggag agcctgttc ttggtgtcaa cgagaaaaca  
 301 cacgtccaac tcagtttgc tgccttcag gtagagacg tgctagtgcg tggcttcggg  
 361 gactctgtg aagaggccct atcggaggca cgtgaacacc tcaaaaatgg cactgtggt  
 421 ctagttagc tggaaaaagg cgtactgcc cagctgaac agccctatgt gttcatta  
 481 cgtctgatg ccttaagcac caatcacggc cacaaggctg ttgagctgtg tgcagaaatg  
 541 gacggcattc agtacggctg tagcgggata acactgggag tactcgtgcc acatgtgggc  
 601 gaaaccccaa ttgcataccg caatgttctt ctctgtaaga acgtaataa gggagccggt  
 661 ggtcatagct atggcatcga tctaaagtct tatgacttag gtgacgagct tggcactgat  
 721 cccattgaag attatgaaca aaactggaac actaagcatg gcagtggtgc actccgtgaa  
 781 ctactcgtg agctcaatgg aggtgcagtc actcgtatg tcgacaacaa ttctgtggc  
 841 ccagatgggt accctctga ttgcatacaa gatttctcg cacgcgcggg caagtcaatg  
 901 tgcacictt ccgaacaact tgattacatc gagtcgaaga gaggtgtcta ctgtgccgt  
 961 gacctgagc atgaaatgc ctggttact gagcgtctg ataagagcta cgagcaccag  
 1021 acaccctcg aaattaagag tgccaagaaa ttgacactt tcaaagggga atgcccacag  
 1081 ttgtgttc ctcttaactc aaaagtcaaa gtcatcaac cacgtgtga aaagaaaaag  
 1141 actgagggt tcatggggcg tatacgtct gtgtaccctg ttgcatctcc acaggagtgt  
 1201 aacaaatgc actgtctac ctgatgaaa tgaatcatt gcgatgaagt tcatggcag  
 1261 acgtgcgact ttctgaaagc cactgtgaa cattgtggca ctgaaaatt agtattgaa  
 1321 ggacctact catgtgggta cctacctact aatgctgtg tgaatgcc atgtccgcc  
 1381 tgtcaagacc cagagattgg acctgagcat agtgtgcag attatcaca ccactcaaac  
 1441 attgaaact gactccgcaa gggaggtagg actagatgt ttgaggctg tgtgttgc  
 1501 tatgttgct gctataataa gcgtgcctac tgggttcctc gtgctagtgc tgatattgc  
 1561 tcaggccata ctggcattac tggtgacaal gtggagacct tgaatgagga tctcctgag  
 1621 atactgagtc gtgaacgtt taacattaac attgtggcg atttcatt gaatgaagag  
 1681 gttgccatca ttgtgcac ttctcgtct tctacaagt ccttatga cactataag  
 1741 agtcttgatt acaagtctt caaaaccatt gttgagtcct gcgtaacta taaagtacc  
 1801 aagggaagc ccgtaaaagg tgcctggaac attggacaac agagatcagt ttaacacca  
 1861 ctgtgtggt tccctcaca ggctgtggt gttatcagat caattttgc gcgcacact  
 1921 gatgcagcaa accactcaat tctgtattg caaagagcag ctgcacat actgatgt  
 1981 atttgaac agtcattacg tctgtcgc gccatggtt atactcaga cctgtcacc  
 2041 aacagtgtca ttattatggc atatgtaact ggtggtctg tacaacagac ttctcagtgt  
 2101 ttgtctaac ttgtggcac tactgtgaa aaactcaggc ctatcttga atggattgag  
 2161 gcgaaacta gtgcaggagt tgaattctc aaggatgcti gggagattct caaattctc  
 2221 attacagggt ttttgacat cgtcaagggt caaatacagg ttgctcaga taacatcaag  
 2281 gattgtgaa aatgctcat tgatgtgtt aacaaggcac tcgaaatgt cattgalcaa  
 2341 gtcactatc ctggcgcaaa gttgcgatca ctcaactag gtgaagtct catcgctcaa  
 2401 agcaaggac ttaccgtca gtgtatacgt ggcaaggagc agctgcaact actcatgct  
 2461 ctaaggcac caaaagaagt aaccttctt gaagggtatt cacatgacac agtactacc  
 2521 tctgaggagg ttgttcaa gaacgggtgaa ctggaagcac tcgagacgcc cgtgatagc  
 2581 ttacaaatg gagctatct cggcacacca gtcgtgtaa atggcctcat gctcttagag  
 2641 attaaggaca aagaacaata ctgcgcattg tctcctggt tactggctac aaacaatgtc  
 2701 ttctgctaa aaggggggtc accaatlaa ggtgtaacct ttggagaaga tactgttgg  
 2761 gaagtcaag gttacaagaa tgtgagaatc acattgagc ttgatgaacg tgtgacaaa

2821 gtgcttaatg aaaagtgtc tgtctacact gttgaatccg gtaccgaagt tactgagttt  
2881 gcatgtgttg tagcagaggc tgttgtaag actttacaac cagtttctga tctccttacc  
2941 aacatgggta ttgatcttga tgagtggagt gtagctacat tctacttatt tgatgatgt  
3001 ggtgaagaaa actttcatc acgtatgtat ttttctttt accctccaga tgaggaagaa  
3061 gaggacgatg cagagtgtga ggaagaagaa attgaigaaa cctgtgaaca tgagtacggt  
3121 acagaggatg attatcaagg tctccctctg gaatttggg cctcagctga aacagttcga  
3181 gttgaggaag aagaagagga agactggctg gatgatacta ctgagcaatc agagattgag  
3241 ccagaaccag aacctacacc tgaagaacca gttaatcagt ttactggta tttaaaact  
3301 actgacaatg ttgccattaa atgtgttgac atcgtaagg aggcacaaag tgctaactct  
3361 atggtgattg taaatgtctg taacatacac ctgaaacatg gtggtgggt agcaggtgca  
3421 ctcaacaagg caaccaatgg tgcctgcaa aaggagagt atgattacat taagctaaat  
3481 ggccctctta cagtaggagg gtctgtttg ctttctggac ataacttgc taagaagtgt  
3541 ctgcatgttg ttgacctaa cctaaatgca ggtgaggaca tccagcttct taaggcagca  
3601 tatgaaaatt tcaattcaca ggacatcta ctgacccat tgtgtcagc aggcataatt  
3661 ggtgctaaac cacttcagtc ttacaagtg tgcgtgcaga cggttcgtac acaggttat  
3721 attgcagta atgacaaagc tcttatgag caggtgtca tggattaat tgataacctg  
3781 aagcctagag tgaagcacc taaacaagag gagccacca acacagaaga ttccaaaact  
3841 gaggagaaat ctgtctaca gaagcctgtc gatgtgaagc caaaaattaa ggctgcatt  
3901 gatgaggta ccacaacact ggaagaaact aagtttcta ccaataagt actctgtt  
3961 gctgatatca atggtgaagt ttaccatgat tctcagaaca tcttagagg tgaagatatg  
4021 tcttctctg agaaggatgc acctacatg gtaggtgat ttactactag tggatatac  
4081 actgtgttg taataccctc caaaaagggt ggtggcacta ctgagatgct ctcaagagct  
4141 ttgaagaaag tgccagtga tgagtatata accacgtacc ctggacaagg atgtgctggt  
4201 tatacactg aggaagctaa gactgtctt aagaaatgca aatctgcat ttatgtacta  
4261 cctcagaag cactaatgc taaggaagag attctaggaa ctgtatctg gaattgaga  
4321 gaaatgctg ctatgctga agagacaaga aaattaatgc ctatatgat ggaattaga  
4381 gccataatg caaccatcca acgtaagtat aaaggaatta aaattcaaga gggcatcgt  
4441 gactatggtg tccgattctt ctttatact agtaagagc ctgtagctt tattattacg  
4501 aagctgaact ctctaaatga gccgctgtc acaatgccaa ttggtatgt gacacatggt  
4561 tttaactctg aagaggctgc gcgctgtat cggtctcta aagctcctgc cgtagtgtca  
4621 gtatcatcac cagatgctgt tactacatat aatggatacc tacttcgtc atcaaagaca  
4681 tctgaggagc actttgtga aacagtttct ttggtgggt ctacagaga ttgtcctat  
4741 tcaggacagc gtacagagt aggtgtgaa ttcttaagc gtggtgacaa aattgtgtac  
4801 cacactctg agagccccgt cgagttcat ctgacgggt aggtcttct actgacaaa  
4861 cttaagagtc tctatccct gcgggaggt aagactataa aagtttcac aactgtggac  
4921 aacactaatc tccacacaca gctgtggat atgtctatga catatggaca gcagtttgt  
4981 ccaacatact tggatggtg tgatgttaca aaaattaaac ctatgtaaa tcatgagggt  
5041 aagactttct ttgtactacc tagtgatgac aactacgta gtgaagctt cgagtactac  
5101 catactctg atgagagttt tcttgtagg tacatgtctg cttaaacca cacaagaaa  
5161 tggaaatttc ctcaagtgg tggtttaact tcaattaaat gggctgata caattgtat  
5221 ttgtctagt tttattagc acttcaacag ctgaagta aattcaatgc accagcact  
5281 caagaggctt attatagagc ccgtgctgt gatgtgcta actttgtgc actcactc  
5341 gcttacagta ataaaactgt tggcgagctt ggtgatgca gagaaactat gacctctt  
5401 ctacagcatg ctaatttga atctgcaaag cgagttcta atgtggtgt taaacatgt  
5461 ggtcagaaaa ctactacctt aacgggtgta gaagctgtga tgtataggg tactctatct  
5521 tatgataatc ttaagacagg ttttccatt ccatgtgtg gtggtcgtga tctacacaa  
5581 tatctagtac aacaagagtc ttcttgtt atgatgtctg caccacctgc tgagtataaa  
5641 ttacagcaag gtacattct atgtgcgaat gactacactg gtaactatca gtgtggtcat  
5701 tacactcata taactgctaa ggagacctc tatcgtattg acggagctca cctacaaag  
5761 atgtcagagt acaaaggacc agtgactgat gtttctaca aggaaacatc ttactaca  
5821 accatcaagc ctgtgtcgt taaactgat ggagttact acacagagat tgaacaaaa  
5881 ttggtgggt attataaaa ggataatgct tactatacag agcagctat agaccttga  
5941 ccaactcaac cattacaaa tgcgagttt gataattca aactcactg tttaacaca  
6001 aaattgtct atgattaaa tcaaatgaca ggctcacaa agccagctc acgagagcta  
6061 tctgtcacat tctcccaga ctgaatggc gatgtagtgg ctattgacta tagacactat  
6121 tcagcgagtt tcaagaaagg tgctaaatta ctgcataagc caattgttg gcacattaac



6181 caggctacaa ccaagacaac gticaaacca aacacttggg gttacgttg tcttggagt  
6241 acaaagccag tagatacttc aaattcattt gaagttctgg cagtagaaga cacacaagga  
6301 atggacaatc ttgcttga aagtcaacaa cccacctcig aagaagtagt ggaaaatcct  
6361 accatacaga aggaagtcac agagtgtgac gtgaaaacta ccgaagttgt aggcaatgtc  
6421 atacttaaac catcagatga aggtgttaaa gtaacacaag agttaggta tgaggatctt  
6481 atggctgctt atgtggaaaa cacaagcatt accattaaga aacctaata gcttacta  
6541 gccttaggtt taaaaacaat tgcactcat ggtatgctg caattaatag ttttcttg  
6601 agtaaaattt tggcttatgt caaaccttc ttaggacaag cagcaattac aacatcaaat  
6661 tgcgctaaga gattagcaca acgtgtgtt aacaattata tgccttatgt gtttacta  
6721 ttgttcaat ttgtacttt tactaaaagt accaattcta gaattagagc ttactacct  
6781 acaactattg ctaaaaatag tttaagagt gttgctaaat tatgttga tgcggcatt  
6841 aattatga agtcaccaa atttctaaa ttgtcaca tcgtatgt gctattgtg  
6901 ttaagtatt gcttaggtt tctaactgt gtaactgtg ctttgggt actctatct  
6961 aatttgggt ctccttcta ttgaatggc gtagagaat tgaatctaa ttgctaac  
7021 gttactacta tggattctg tgaaggtct tttcttga gcattgtt aagtgatta  
7081 gactccctg attctatcc agctctgaa accattcagg tgacgattc atcgtacaag  
7141 ctgactga caatttagt tctggccgt gagtgggtt tggcatatat gttgtcaca  
7201 aaattcttt attattagg tcttcagct ataatgcagg tttcttgg ctatttct  
7261 agtcattca tcagcaattc ttgctcatg ttgttatca ttattgtt acaaatggca  
7321 cccgttctg caatggtag gatgtacac ttttctt ctttacta cataggaag  
7381 agctatgtc atatcatga tgggtgcacc tctcgactt gcatgatgt ctataagcg  
7441 aatcgtcca cagcgtga gtgtacaact attgtaatg gcatgaagag atcttctat  
7501 gtctatgcaa atggaggccg tggctctgc aagactcaca attggaattg tctcaattg  
7561 gacacattt gcactgtag tacattcatt agtgatgaag ttgctctga ttgtcact  
7621 cagtttaaaa gaccaatcaa cctactgac cagtcactgt atattgtga tagtgtgt  
7681 gtgaaaaatg gcgcttca cctctactt gacaaggct gtcaaaagac ctatgagaga  
7741 catccgtct cccatttct caatttagac aattgagag ctacaacac taaagggtca  
7801 ctgcctatta atgtcatagt ttgtatggc aagtcctaat gcgacgagtc tgccttaag  
7861 tctgtctg ttactacag tcagctgat tgcacaccta tctgtgtg taccagct  
7921 ctgtatcag acgttgaga tagtactga gttccgtta agatgttga tctatgtc  
7981 gacaccttt cagcaactt tagtgtct atggaaaaac ttaaggcact ttgtctaca  
8041 gctcacagcg agttagcaaa ggtgttagt ttataggtg tcttctac attcgtgca  
8101 gctgccgac aaggtgtgt tgataccgat ttgacacaa aggatgtat tgaatgtc  
8161 aaacttcac atcactctga ctagaagt acaggtgaca gtgtaacaa tttcatgtc  
8221 acctataata aggtgaaaa catgacgcc agagatctg gcgcatgtat tgaatgaat  
8281 gcaaggcata tcaatgcca agtagcaaaa agtcacaat ttactcat ctggaatga  
8341 aaagactaca tctttatc tgaacagct cgtaacaaa ttctagtgc tccaagaag  
8401 aacaacatac ctttagact aactgtgt acaactagac aggtgtcaa tgcataact  
8461 actaaaatc cactcaagg tggtaagatt gtagtactt gtttaaaact tatgttaag  
8521 gccacattt ttgtgtct tctgcatg gttgttata tcttatgcc agtacatac  
8581 ttgcaalc atgatgtta cacaatgaa atcattggt acaagccat tcaggatgt  
8641 gtcactgt acatcattc tactgatgt tttttgcaa ataaacatg tggtttgc  
8701 gcatggtta gccagcgtg tggtcatac aaaaatgaca aaagctgcc ttagtagct  
8761 gctatcata caagagagt tggttcata gtgcctggt taccgggtac tgtctgaga  
8821 gcaatcaat gtgactct gcatttcta cctcgtgt ttatgtgt tggcaacatt  
8881 tctacacac ctccaaact catgagat agtgattt ctactctgc ttgcttct  
8941 gctgtgagt gtacaattt taaggatgt atgggcaaac ctgtccata ttgtatga  
9001 actaattgc tagagggtc tattctat agtgagct gtccagacac tcttatgt  
9061 ctatggatg gtccatcat acagttct aacacttacc tggagggtc tttagagta  
9121 gtaacaact ttatgtga gtactgaga catgtacat gcgaaaggtc agaagtagt  
9181 attgcctat ctaccagt tagatgggt ctaataatg agcatcac agctatca  
9241 ggagtttct gtgtgtga tgcgatga ctcatagcta acatcttac tctctgtg  
9301 caacctgtg gtgtttaga ttgtctgt ttagtagtg ctggtgtat tattccata  
9361 ttgtgact gtgtgcta ctacttat aaatcagac gtgttttg ttagtacaac  
9421 catgtgtg ctgcaatgc actttgtt ttatgtct tctatact ctgtctga  
9481 ccagctaca gcttctgcc gggagtct ttagtctt actgtact gacattat

9541 ttcaccaatg atgtttcatt ctggctcac ctcaatggt ttgcatgtt ttctctatt  
9601 gtgcctttt ggataacagc aatctatgta ttctgtattt ctctgaagca ctgccattgg  
9661 ttctttaaca actatcttag gaaaagagtc atgtttaatg gagttacatt tagtaccttc  
9721 gaggaggctg ctttgtgtac cttttgtc aacaaggaaa tgtacctaaa attgcgtagc  
9781 gagacactgt tgcacttac acagtataac aggtatcttg ctctataaa caagtacaag  
9841 tatttcagtg gagccttaga tactaccagc tatcgtgaag cagcttgctg ccacttagca  
9901 aaggctctaa atgacttag caactcaggt gctgatgtc tctaccaacc accacagaca  
9961 tcaatcactt ctgctgttct gcagagtggg tttaggaaaa tggcattccc gtcaggcaaa  
10021 gttgaagggt gcatggtaca agtaacctgt ggaactacaa ctctaatgg attgtggtg  
10081 gatgacacag tatactgtcc aagacatgtc attgcacag cagaagacat gcttaatcct  
10141 aactatgaag atctgtcat tgcacaaacc aaccatagct ttctgttca ggctggcaat  
10201 gttcaacttc gtgtattgg ccatctatg caaaattgtc tgcctaggct taaagtgtat  
10261 acttctaacc ctaagacacc caagtataaa ttgtccgta tccaacctgg tcaaacattt  
10321 tcagttctag catgtacaa tggttacca tctggtgtt atcagtgtc catgagacct  
10381 aatcatacca taaagggtc ttcttaat ggatcatgtg gtatgtgtg tttaacatt  
10441 gattatgatt gcgtgtctt ctgtatatg catcatatgg agctccaac aggagtacac  
10501 gctgtactg actagaagg taaattctat ggtccattg ttgacagaca aactgcacag  
10561 gctgcaggta cagacacaac cataacatta aatgtttgg catggctgta tgcgtgtgt  
10621 atcaatgggt atagggtgtt tctaataga ttcaccacta cttgaatga ctttaacctt  
10681 gtggcaatga agtacaacta tgaaccttg acacaagatc atgttgacat attgggacct  
10741 cttctgtc aaacaggaat tgcgtctta gatagtgtg ctgcttgaa agagctgtg  
10801 cagaatggtg tgaatgtcg tactatcctt gtagcacta tttagaaga tgagttaca  
10861 ccatttgatg ttgttagaca atgctctgtt gttacctcc aaggtaagt caagaaaatt  
10921 gtaaggga ccatcatg gatgcttta acttctga catcactatt gattctgtt  
10981 caaagtacac agtggctact gtttctt gttacgaga atgcttctt gccattact  
11041 cttgttatta tggcaattgc tcatgtgt atgctgtt taaacataa gcacgcattc  
11101 ttgtgtgt ttctgtacc ttctgtga acagtgtt acttaatat ggtctacatg  
11161 cctgttagct gggtagcg tatcatgaca tggctgaat tggctgacac tagctgtct  
11221 ggttataggc taaaggattg tttatgtat gcttcagct tagtttctt tattctatg  
11281 acagctcgca ctgttatga tgatgtgt agacgtgtt ggacactgat gaatgtcatt  
11341 acactgttt acaaagtcta ctatggtaat gcttagatc aagctattc catgtgggc  
11401 ttatgtatt ctgtaacct taactattt ggtgtctga cgactatcat gtttagct  
11461 agagctatag tttgtgtg ttgtagtat taccattgt tattattac tggcaacacc  
11521 ttacagtga tcatgtgt ttattgtt ttaggtatt gtgtgtgt ctacttggc  
11581 ctttctgt tactcaaccg ttactcagg ctactctg gtgttatga ctacttggc  
11641 tctacacaag aattaggta tatgaactcc caggggctt tgcctcctaa gagtagtatt  
11701 gatgcttca agctaacat taagtgtg ggtattggag gtaaaccatg tatcaagggt  
11761 gctactgtac agtctaaaat gtctgacgta aagtgcacat ctgtggtact gctctcgtt  
11821 ctcaacaac tttagtaga gtcattctt aaattgtgg cacaatgtg acaactccac  
11881 aatgatatt ttctgcaa agacacaact gaagcttgc agaagatgtt ttctcttg  
11941 tctgtttgc tatcatgca ggtgtgtg gacattaata ggtgtgca ggaaatgctc  
12001 gataaccgtg ctactctca ggtattgt tcaaatga gttcttacc atcatatgcc  
12061 gcttatgcca ctgccagga ggcctatgag caggtgtg ctatgggtga ttctgaagtc  
12121 gttctcaaaa agttaaagaa atcttgaat tggctaaat ctgagttga cgtgatgt  
12181 gccatgcaac gcaagtga aaagatggca gatcaggcta tgacccaaat gtacaaacag  
12241 gcaagatctg aggacaagag ggcaaaagta actagtgtga tgcaacaat gctcttact  
12301 atgcttagga agctgataa tgatgcatt aacaacatta tcaacaatgc gcgtgatgt  
12361 tgtgtccac tcaacatcat accattgact acagcagcca aacatgtgt tgtgtcct  
12421 gattatggt cctacaagaa cactgtgtat ggtaacacct ttacatatgc atctgcactc  
12481 tgggaaatcc agcaagtgt tgatgctgat agcaagattg tcaacttag tgaaataac  
12541 atggacaatt caccaaatg gcttggcct ctattgtta cagcttaag agccaactca  
12601 gctgttaaac tacagaataa tgaactgagt ccagtgtcac tgcacagat gtctgtgcg  
12661 gctgttacca cacaacagc ttgtatgat gacaatgcac tgcctacta taacaattcg  
12721 aaggagggtg ggtgtgtc ggcattacta tgcaccacc aagatctcaa atgggctaga  
12781 ttccctaaga gtatgtgt aggtacaatt tacacagaac tgaaccacc ttgtagggtt  
12841 gttacagaca caccaaaagg gcctaaagt aaatactgt acttcatca aggcttaac

12901 aacctaata gaggtatggt gctgggcagt ttgctgcta cagtacgtct tcaggctgga  
12961 aatgctacag aagtacctgc caattcaact gtgcttcct tctgtgctt tgcagtagac  
13021 cctgctaaag catataagga ttacctagca agtggaggac aaccaatcac caactgtgtg  
13081 aagatgtgt gtacacacac tggtagga caggcaatta ctgtaacacc agaagctaac  
13141 atggaccaag agtccttgg tgggtctca tgggtctgt atttagatg ccacattgac  
13201 catccaaatc ctaaaggatt ctgtgacttg aaaggtaagt acgtccaaat acctaccact  
13261 tgtgctaag acccagtggg ttctacatt agaaacacag tctgtaccgt ctgcggaatg  
13321 tggaaagggt atggctgtag ttgtgacca ctcgcgaac cctgatgca gtctgcggat  
13381 gcatcaacgt ttttaacgg gttgctgtg taagtgcag cctgttaca cctgtcggca  
13441 caggcactag tactgatgt gtctacagg ctttgatat ttacaacgaa aaagtgtctg  
13501 gtttgcaaa gtctcaaaa actaattgt gtgcttcca ggagaaggat gaggaaggca  
13561 atttattaga ctctacttt gtagttaaga ggcatactat gtctaactac caacatgaag  
13621 agactattha taacttggt aaagattgtc cagcgggtgc tgtccatgac ttticaagt  
13681 tttagtaga tggtagatg gtaccacata taccagtca gcgtctaact aaatacacia  
13741 tggctgatt agtctatgt ctacgtcatt ttgatgagg taattgtat acattaaaag  
13801 aaatactgt cacatacaat tctgtgatg atgattatt caataagaag gattggtatg  
13861 acttctaga gaatcctgac atctacgag tatatgtaa cttaggtgag cgtgtacgcc  
13921 aatcattatt aaagactgt caattctgc atgtatgag tgatgcaggc atttagggc  
13981 tactgacatt agataatcag gatctaatg ggaactggt cgattcgtt gatttctac  
14041 aagtagcacc aggtgcgga gtctctatt tggaticata ttactcatt ctgatgcca  
14101 tctcacatt gactaggga tggctgctg agtccatat gtagctgat ctgcataaac  
14161 cactattaa gtgggattg ctgaaatag atttaccga agagagact tgcctctg  
14221 accgttatt taaatattg gaccagacat accatccaa ttgtattac tgttggtg  
14281 atagggtat cctcattgt gcaaaacta atgtgtatt ttactgtg ttccaccta  
14341 caagtttg accactagta agaaaaatat ttgtatagg tttccttt gtgtttcaa  
14401 ctggatacca ttctgtgag ttaggagtc tacataatca gtagtaaac ttacatagct  
14461 cgcgtctag ttcaaggaa ctttagtgt atgtgtgta tccagctat catgcagct  
14521 ctggcaatt atgtctat aaacgcacta catgctttc agtagctga ctaacaaaca  
14581 atgtgctt tcaaacgtc aaacccggt atttaataa agactttat gacttctg  
14641 tgtctaaag ttctttaag gaaggaagt ctgtgaact aaaacactt tcttctg  
14701 aggatggcaa cgtgctatc agtgattat actattatc ttataatct ccaacaatg  
14761 gtgatacag acaactccta tctgtatg aagttgtga taaatactt gattgtacg  
14821 atgttgctg tattaatgcc aaccaagta tcttaacaa tctggataaa tcagctggt  
14881 tccatttaa taaatgggt aaggctagac ttattatga ctcaatgag tatgagatc  
14941 aagatgcact ttctgctat actaagcgt atgtatccc tactataact caaatgaatc  
15001 ttaagtatg cattagtga aagaatagag ctgcaccgt agctggtgc tctatctga  
15061 gtactatgac aaatagacag ttcatcaga aattattga gtcaatagcc gccactagag  
15121 gagctactgt ggtaattgga acaagcaagt ttacgggtg ctggcataat atgttaaaaa  
15181 ctgtttacag tgatgtaga actccacacc ttatgggtg ggattacca aaatgtgaca  
15241 gagccatgcc taacatgct aggataatg cctctctgt tctgtctgc aaacataaca  
15301 ctgtctgaa ctatcacac cgtttctaca ggttagctaa cgagtgtgc caagtattaa  
15361 gtgagatggt catgtgtgg ggctcactat atgttaaacc aggtggaaca tcatccggtg  
15421 atgtacaac tcttatgt aatagtgt ttacattt tcaagctgt acagccaatg  
15481 taaatgcact tcttcaact gatggaata agatagctga caagtatgc cgcaatctac  
15541 aacacaggct ctatgagt ctctatagaa ataggatgt tgatcatgaa ttctggatg  
15601 agttttacgc ttactgcgt aaacattct ccatgatg tcttctgat gatccgtg  
15661 tgtgtataa cagtaactat gcggcicaag gtttagtag tagcataag aacttaagg  
15721 cagttctta ttatcaaat aatgtgtca tgtctaggc aaaagtgt actgagactg  
15781 acctactaa aggacctac gaatttct cacagcaca aatgctagt aaacaaggag  
15841 atgattacgt gtacctgcct taccagatc catcaagaat attaggcgca ggctgtttg  
15901 tcatgatat tgcataaca gatgtacac ttatgattga aaggtctgt tcatggcta  
15961 ttgatgcta ccacttaca aaacatcta atcaggagta tctgtatgt ttacttgt  
16021 atttacaata cattagaaag ttacatgat agcttactgg ccacatgtg gacatgtatt  
16081 ccgtaatgt aactaatgt aacacctac ggtactgga acctgagtt tatgaggcta  
16141 tgtacacac acatacagc ttgcaggctg taggtctgt tgtattgtc aattcacaga  
16201 ctctactct tgcgggtgc tgtattagga gaccattct atgttgaag tctgtctatg

16261 accatgtcat ttaacatca cacaattag tgtgtctgt taatccctat gttgcaatg  
16321 cccaggttg tgaatgact gatgtgacac aactgtatct aggaggtatg agctattatt  
16381 gcaagtcaca taagcctccc attagtttc cattatgtgc taatggtag gttttggt  
16441 tatacaaaaa cacaatgtga ggcagtgaca atgtcactga ctcaatgag atagcaacat  
16501 gtgattggac taatgtggc gattacatac ttgccaacac ttgtactgag agactcaagc  
16561 ttttcgagc agaaacgctc aaagccactg aggaacatt taagctgtca tatggtattg  
16621 ccactgtacg cgaagtactc tctgacagag aattgcatct tcatgggag gttggaaaac  
16681 ctgaccacc attgaacaga aactatgtct ttactggta ccgtgtaact aaaaatagta  
16741 aagtacagat tggagagtac accttgaaa aaggtagta tggtagtct gttgtgaca  
16801 gaggtactac gacatacaag ttgaatgtg gtgattact tgtgtgaca tctcactg  
16861 taatgccact tagtgacct actctagtgc cacaagagca ctatgtgaga attactggct  
16921 tgtaccaac actcaacatc tcagatgagt ttctagcaa tttgcaa atcaaaagg  
16981 tcggcatgca aaagtactct acactccaag gaccacctgg tactggtaag agtcatttg  
17041 ccatcggact tgctctctat taccatctg ctgcctagt gtatcggca tgctctatg  
17101 cagctgtga tgccctatgt gaaaaggcat taaaatatt gccatagat aatgtagta  
17161 gaatcatacc tgcgctgag cgcgtagagt gtttgataa attcaaagt aattcaacac  
17221 tagaacagta tgtttctgc actglaaag cattgccaga aacaactgct gacattgtg  
17281 tctttgatga aatctctatg gctactaat atgactgag tgtgtcaat gctagactc  
17341 gtgcaaaaca ctacgtctat attggcagc ctgctcaat accagcccc cgcacattgc  
17401 tgactaaagg cacactagaa ccagaatatt ttaattcagt gtgcagact atgaaaaca  
17461 taggtccaga catgttctt ggaactgtc gccgtgtcc tgcgaaat gttgacactg  
17521 tgagtgtt agttatgac aataagtaa aagcacaca ggataagtca gctcaatgt  
17581 tcaaatgt ctacaaagg gttattacac atgatgttc atctgcaat aacagacctc  
17641 aataggcgt tgaagagaa ttcttacac gcaatctgc ttggagaaa gctgtttta  
17701 tctcaccta taattcacag aacgtgtg ctcaaaaat ctaggattg cctacgcaga  
17761 ctgtgtatc atcacagggt tctgaatat actatgtcat attcacaca actactgaaa  
17821 cagcacactc ttgaatgtc aaccgctca atgtggctat cacaaggga aaaattggca  
17881 tttgtgcat aatgtctat agagatctt atgacaaat gcaattaca agtctagaa  
17941 taccagtcg caatgtggt acattacaag cagaaaatgt aactggact ttaaggact  
18001 gtagtaagat ctactgtt ctcatccta cacaggcacc tacacacctc agcgtgata  
18061 taaagtcaa gactgaagga ttatgtgtg acataccagg catacaaag gacatgacct  
18121 accgtagact catctctat atgggttca aatgaatta ccaagtcaat ggttacccta  
18181 atatgttat ccccgcgaa gaagctatc gtcacgttcg tgcgtggatt ggcttgatg  
18241 tagagggtc tcatgcaat agagatgtc tgggtactaa cctacctc cagctaggat  
18301 ttctacagg ttttaacta gtacgtgac cgactggta tttgacact gaaaataaca  
18361 cagaattcac cagagtta gcaaaacct caccaggta ccagttaaa catctatac  
18421 cactcatgta taaaggctg ccttggaat tagtgctat taagatagta caaatgctca  
18481 gtgatacact gaaaggattg tcagacagag tctgttct ctttggcg catggcttg  
18541 agcttacat aatgaagtac ttgtcaaga ttgacctga aagaacgtgt tctgtgtg  
18601 acaaacgtgc aactgtct tctactcat cagatacta tgcctgctg aatcattctg  
18661 tgggtttga ctatgtctat aaccattta gtattgatg tcagcagtg ggcttacgg  
18721 gtaacctca gataacct gaccaacatt gccaggata tggaaatgca catgtggcta  
18781 gttgtatgc tatcatgact agatgttag cagtcctga gtgcttgt aagcgcgtg  
18841 attgtctgt tgaataacct attataggag atgaactgag ggttaattct gctgcagaa  
18901 aagtacaaca catggtgtg aagtctgcat tctgtctga taagtcca gtctcatg  
18961 acattgaaa tcaaaggct atcaagtgt tgcctcaggc tgaagtagaa tggagttct  
19021 acgatgctca gccatgagt gacaaagctt acaaataga ggaactctc tattctatg  
19081 ctacacatca cgataaatc actgatgtg ttgtttgt ttggaattgt aacgtgac  
19141 gttaccagc caatgcaat gtgtgtagt ttgacacaag agtctgtca aactgaact  
19201 taccaggctg tgatgtgt agttgtatg tgaataagca tgcattccac actccagct  
19261 tggataaaa tgcattact aattaaagc aattgcctt ctttactat tctgatagc  
19321 ctgtgtatc tcatggcaa caagtagtg cggatattga ttatcca ctcaaatctg  
19381 ctacgtgat tacacgatg aattagggt gtgctgtt cagacacct gcaaatgagt  
19441 accgacagta ctggatgca tataatatg tgaattctg tggattagc ctatggatt  
19501 acaacaatt tgatactat aacctgtga atacattac caggttacag agtttagaa  
19561 atgtggcta taatgtgt aataaggac acttgatgg acacgccgc gaagcacctg




19621 ttccatcat taataatgct gtttacacaa aggtagatgg tattgatgtg gagatctttg  
19681 aaaataagac aacacttcct gtaaatgttg cattgagct ttgggctaag cgtaacatta  
19741 aaccagtgcc agagattaag atactcaata atttgggtgt tgatacgtc gctaatactg  
19801 taatctggga ctacaaaaga gaagccccag cacatgtatc tacaataggc gctgcacaa  
19861 tgactgacat tgccaagaaa cctactgaga gtgctgttc ttacttact gtctgtttg  
19921 atggtagagt ggaaggacag gtagacctt ttgaaacgc ccgtaatggc gtttaataa  
19981 cagaagggtc agtcaaaggc ctaacacctt caaagggacc agcacaagct agcgtcaatg  
20041 gagtcacatt aattggagaa tcagtaaaaa cacagttaa ctacttaag aaagtagacg  
20101 gcattattca acagttgctt gaaacctact ttactcagag cagagactta gaggattta  
20161 agcccagatc acaaatggaa actgacttcc tcgagctcgc tatggatgaa ttacacagc  
20221 gatataagct cgagggtat gccttcgaac acatcgttta tggagattc agtcatggac  
20281 aacttggcgg tcttcattta atgataggc tagccaagcg ctacaagat tcaccactta  
20341 aattagagga tttatccct atggacagca cagtgaataa ttactcata acagatgcgc  
20401 aaacagggtc atcaaatgt gtgtgtctg tgattgatct ttacttgat gactttgtc  
20461 agataataaa gtcacaagat ttgtcagtga ttcaaaagt ggtcaagggt acaatgact  
20521 atgctgaaat ttatcatg ctttgggtga aggatggaca tgtgaaac ttctaccaa  
20581 aactacaagc aagtcgagcg tggcaaccag gtgttcgat gcctaactg tacaagatgc  
20641 aaagaatgct tctgaaaag tgtgacctc agaattatgg tgaatgct gttalacca  
20701 aaggaataat gatgaatgc gcaaagtata ctcaactgt tcaactta aatacactta  
20761 ctttagctgt accctacaac atgagagta ttactttg tctggctct gataaaggag  
20821 ttgcaccagg tacagctgt ctacagacaat ggttgccaac tggcacacta ctgtcgatt  
20881 cagatcttaa tgactcgtc tccgacgc atctactt aattggagac tgtcaacag  
20941 tacatacggc taataaatgg gaccttata ttacgatat gtatgacctt aggaccaaac  
21001 atgtgacaaa agagaatgac tctaaagaag ggttttcac ttatctgtt ggattataa  
21061 agcaaaaact agccctgggt ggttctatag ctgtaaagt aacagagcat tcttgaatg  
21121 ctgacctta caagctatg ggccattct catgttgac agctttgtt acaaatgta  
21181 atgcatcatc atcggaagca ttttaattg gggctaacta tctggcaag ccgaaggaa  
21241 aaattgatg ctatacatg catgctaact acatttctg gaggaacaca aatctatcc  
21301 agttgtctc ctatcactc ttgacatga gcaaattcc tctaaatta agaggaaact  
21361 ctgtaatgtc tcttaaggag aatcaaatca atgatgat ttatctct ctggaaaag  
21421 gtaggctat cattagagaa aacaacagag ttgtgttc aagtatatt ctgttaaca  
21481 actaaacgaa catgttatt tcttattat ttctactc cactagtgt agtgacctg  
21541 accgggtcac cactttgat gatgtcaag ctctaatta cactcaacat actcatcta  
21601 tgaggggggt ttactatct gatgaaatt ttgatcaga cactcttat ttaactcagg  
21661 atttattct tcaattat tctaagtta cagggttca tactattaat catacgttg  
21721 gcaacctgt cataccttt aaggatggt tttatttgc tggcacagag aatcaaatg  
21781 ttgtccgtg ttgggtttt ggttctacca tgaacaacaa gtcacagtc gtgatttta  
21841 ttaacaatt tactaatgt gttatagag catgtaact tgaattgtg gacaacctt  
21901 tcttgcgt tctaaacct atgggtacac agacacatac tatgattc gataatgat  
21961 ttaattgcac ttcgagtac atatctgat cctttcgt tgatgttca gaaaagtcag  
22021 gtaatttaa acacttacga gagtttgt taaaaataa agatgggtt ctctatgtt  
22081 ataagggt tcaacctata gatgtgtc gtatctacc ttctgttt aacacttga  
22141 aacctatt taagttgct ctgttatta acattacaaa tttagagcc attctacag  
22201 cctttcacc tgcacaagac atttggggca cgtcagctgc agctattt gttggctatt  
22261 taaagccaac tacattatg ctcaagtat atgaaaatg tacaacaca gatgtgtg  
22321 attgttca aaatccact gctgaactca aatgctgt taagagctt gagattgaca  
22381 aaggaattta ccagacctt aattcaggg ttgtccctc aggagatgt gtgagattc  
22441 ctaatatt aaacttgt cctttggag aggtttta tgcactaaa ttccctctg  
22501 tctatgat ggagagaaaa aaaatttcta attgtgtg tgattact gtgtctaca  
22561 actcaacatt tttcaacc ttaagtgt atggcgttc tggcactaag ttgaatgat  
22621 ttgtctc caatgtct gcagattct ttgtatcaa gggagatgt gtaagacaaa  
22681 tagcgcagg acaactgt gttatgtc attataata taaattgcca gatgttca  
22741 tgggtgtgt cctgtctg aatactagga acattgatc tactcaact ggaattata  
22801 attataata taggtatct agacatggca agctaggcc cttgagaga gacatatcta  
22861 atgtgcctt cccccgat ggcaaacct gacccacc tgcctaat tgtattggc  
22921 cattaaatga ttatgttt tacaccacta ctggcattg ctaccaacct tacagagtg

22981 tagtactttc ttggaactt ttaaatgcac cggccacggt ttgtggacca aaattatcca  
23041 ctgaccttat taagaaccag tgggtcaatt ttaattttaa tggactcaat ggtactgggt  
23101 tggtaactcc ttctcaaag agattcaac cattcaaca attggccgt gatgttctg  
23161 atttactga ttccgtcga gatcctaaaa catctgaaat attagacatt tcacctgcg  
23221 ctttggggg tgaagtga attacacctg gaacaaatgc ttcatctgaa gttgctgtc  
23281 tatalcaaga tggtaactgc actgatgtt ctacagcaat tcatgcagat caactcacac  
23341 cagcttggcg catatatct actggaaca atgtattcca gactcaagca ggctgtctta  
23401 taggagctga gcatgtcga acttctatg agtgcgacat tctattgga gctggcatt  
23461 gtgctagta ccatacagtt tcttattac gtagtactag ccaaaaaatct attgtggct  
23521 atactatgc tttaggtgct gatagtcaa ttgcttact taataacacc attgtatac  
23581 ctactaact ttcaattagc attactacag aagtaatgcc tgttctatg gctaaaacct  
23641 ccgtagattg taatatgtac atctgcggag atttactga atgtgctaatt ttgcttctc  
23701 aatatggtag ctttgcaca caactaaatc gtgcactctc aggtattgct gctgaacagg  
23761 atcgcaacac acgigaagt ttcgtcaag tcaacaaat gtacaaaacc ccaacttga  
23821 aatatttgg tggtttaatt ttccacaaa tattacctga cctctaaag ccaactaaga  
23881 ggcttttat tgaggactg ctcttaata aggtgacact cgctgatgct ggctcatga  
23941 agcaatatgg cgaatgccta ggtgatatta atgctagaga tctcattgt gcgcagaagt  
24001 tcaatggact tacagtgtg ccacctcgc tcatgtatga tatgattgct gctacactg  
24061 ctgctctagt tagtggtact gccactcgt gatggacatt tgggtcgtgc gctgctctc  
24121 aaataacctt tgcatacaa atggcatata ggtcaatgg cattggagt acccaaatg  
24181 ttctatga gaacaaaaa caaatcgcca accaattaa caaggcgatt agtcaaatc  
24241 aagaatcact tacaacaaca tcaactgcat tgggcaagct gcaagacgt gtaaccaga  
24301 atgctcaagc attaaacaca ctgttaaac aacttagctc taatttggg gcaattcaa  
24361 gtgtgctaaa tgatacctt tgcgactg ataaagtga ggcggaggta caaattgaca  
24421 ggtaattac aggcagact caaagcctc aaacctatgt aacacaaca ctaacaggg  
24481 ctgctgaaat cagggtctt gctaacttg ctgctactaa aatgtctgag tgtgtctg  
24541 gacaatcaaa aagagttgac ttgtggaa agggctacca cctatgtcc ttccacaag  
24601 cagccccga tgggtgtgc ttctacatg tcacgtatgt gccatccag gagaggaact  
24661 tcaccacagc gccagcaatt tgcataag gcaaagcata ctccctcgt gaagggttt  
24721 ttgttttaa tggcactct tggttatta cacagaggaa ctctttct ccacaaataa  
24781 ttactacaga caatacatt gtctcaggaa attgtatgt cgttattggc atcattaaca  
24841 acacagtta tgatccttg caacctgagc ttgactcat caaagaagag ctggacaagt  
24901 actcaaaaa tcatatca ccagatgtg atcttggca cattcaggc attaacgct  
24961 ctgtcgtcaa cattcaaaaa gaaattgacc gcccaatga ggtcgctaaa aatttaaatg  
25021 aalcacat tgacctcaa gaattggaa aalatgagca atatattaaa tggccttgg  
25081 atgttggct cggctcatt gctggactaa ttgccatgt catggtaca atcttctt  
25141 gtgcatgac tagtgtgc agtgcctca aggtgcatg ctctgtgtg tctgtgca  
25201 agttgatga ggtgactct gagccagtc tcaagggtg caaattacat tacacataa  
25261 cgaactatg gattgtta tgagattt tactcttga tcaattactg cacagocagt  
25321 aaaaatgac aatgctctc ctgcaagtac tgtcatgt acagcaacga taccgtaca  
25381 agcctactc ccttcggat ggctgttat tggcgttga ttctgtg ttctcagag  
25441 cgctacaaa ataattgct tcaataaaag atggcagct gcccttata agggctcca  
25501 gtcatgtc aattactgc tgcattgt taccatctat tcacatctt tgcgtgcg  
25561 tgcaggtat gaggcgcaat ttgtacct ctatgcctg atatatttc tacaatgat  
25621 caacgatgt agaattata tgagatgtg gcttgttg aagtgcaat ccaagaacct  
25681 attacttat gatgcaact acttgttg ctggcacaca cataactatg actactgtat  
25741 accatatac agtgcacag atacaattgt cgttactga ggtgacgga ttcaacacc  
25801 aaaactcaa gaagactacc aaattggtg ttattctgag gataggcact cagggttaa  
25861 agactatgc gttgtacat gctattcac cgaagttaac taccagctg agtctacaca  
25921 aattactaca gacactggt tgaaaatgc tacattctc atcttaaca agctgttaa  
25981 agaccaccg aatgtcaaa tacacacaat cgacggctct taggagtig ctaatccagc  
26041 aatggatcca attatgat agccgacgac gactactagc gtgccttgt aagcacaaga  
26101 aagtgagac gaactatgt actcattcgt tccgaagaa acaggtagt taatgttaa  
26161 tagcgtact ctttcttg ctctgtgt attctgcta gtcacactag ccactctac  
26221 tgcgctcga ttgtgtcgt actgtgcaa tattgtaac gtgagttag taaaaccaac  
26281 ggtttacgc tactcgcgt taaaaatct gaactctct gaaggagtc ctgatctct




26341 ggtctaaacg aactaactat tattattatt ctgtttggaa cttaacatt gcttatcatg  
26401 gcagacaacg gtactattac cgttgaggag cttaacaac tcttggaca atggaacctt  
26461 gtaatagggt tctatttct agcctggatt atgttactac aattgccta ttctaactcg  
26521 aacagggttt tgtacataat aaagcttgt ttctctggc tcttggcc agtaacactt  
26581 gcttgtttg tgcctgtgc tgtctacaga attaatggg tgaactggg gattgcgatt  
26641 gcaatggctt gtattgtagg ctgtatgtg cttagctact tcttgcctt cttcaggctg  
26701 ttgtctgta cccgtcaat gtggctatc aaccagaaa caaacattt tctcaatgtg  
26761 cctctccggg ggacaattgt gaccagaccg ctcatggaaa gtgaactgt cattgtgtct  
26821 gtgatctt cgtgtcact gcgaatggc ggacactccc tagggcgctg tgacattaag  
26881 gacctgcaa aagagatcac tgtggctaca tcacgaacgc ttcttatta caaatagga  
26941 gcgtgcagc gtgtaggca tgaactagg ttgtctcat acaaccgcta cgtattgga  
27001 aactataaat taaatacaga ccacgccgt agcaacgaca atattgctt gctagtacag  
27061 taagtacaa cagatgtt atcttgtga ctccagggt acaatagcag agatattgat  
27121 tatcattatg aggacttca ggattgctat ttgaatctt gacgtataa taagtcaat  
27181 agtgagacaa ttattagc ctctaactaa gaagaattat tggagttag atgatgaaga  
27241 acctaggag ttgattatc cataaaacga acatgaaaat tttctctt ctagattga  
27301 ttgtattac atctgcgag ctatatcact atcaggagt ttttagaggt acgactgtac  
27361 tactaaaaga acctgcca tcaaggaacat acgagggcaa taccattt caccctctg  
27421 ctgacaataa attgcacta actgcacta gcacacact tgccttctg tgtctgacg  
27481 gtactcgaca tacctatcag ctgcgtgcaa gatcagttt accaaaact tcatcagac  
27541 aagaggaggt tcaacaagag ctctactgc cacttttct cattgtgtct gcttagtat  
27601 tttaatact ttgcttacc attagagaa agacagaatg aatgagctca cttaattga  
27661 ctctattg tgcctttag ccttctgct attcctgtt taataatgc ttattatatt  
27721 ttggtttca ctgaaatcc aggatctaga agaactgt accaaagtct aaacgaacat  
27781 gaaacttct attgtttga ctgtattt tctatgcagt tcatatgca ctgtatga  
27841 gcgtgtgca tctaataac ctcatgtct tgaagatct tgaaggta aacactaggg  
27901 gtaatactta tagcactgt tggcttgt ctctaggaaa ggtttacct ttcatagat  
27961 ggcacactat ggtcaaca tgcacaccta atgttact caactgtca gatccagctg  
28021 gtgtgtcgt tatagctagg tgtgtgacc tcatgaagg taccaaaact gctgcattta  
28081 gagacgtact tgtgttta aataaacgaa caaattaaa tgtctgataa tggacccaa  
28141 tcaaaccaac gtatgcccc ccgattaca ttgttgac ccacagatt aactgacaat  
28201 aaccagaatg gaggacgcaa tggggcaagg ccaaacagc gccgaccca aggttacc  
28261 aataatactg cgtctggt cagactct actcagcat gcaaggagga acttagatt  
28321 cctcaggcc agggcgtt aatcaacacc aatagtgt cagatgacca aattggctac  
28381 taccgaagag ctacccgac agtctgtgt ggtgacgga aatgaaaga gtcagcccc  
28441 agatgtact tctattact aggaactgg ccagaagct cacttcccta cggcgctaac  
28501 aaagaaggca tctatgggt tgaactgag ggagcctga atacaccaa agaccacatt  
28561 ggcaccgca atcctaata caatgtgcc accgtgtac aacttctca aggaacaaca  
28621 ttgcaaaaag gcttctacg agagggaagc agaggcgga gtcaagctt tctcgtcc  
28681 tcatcagta gtgcggtta tcaagaaat tcaactctg gcagcagtag gggaaattt  
28741 cctgctgaa tggctagcg aggtgtgaa actgcccctg cgtattgt gctagacaga  
28801 tgaaccagc ttgagagca agttctgtt aaaggccaac aacaacaagg ccaactgtc  
28861 actaagaaat ctgtgtga ggcattaaa agcctcgc aaaaacgtac tgccacaaa  
28921 cagtacaacg tactcaagc atttggaga cgtgtccag acaaaccca aggaattt  
28981 gggaccaag acctaatcag acaaggaact gattacaaac attggccgca aattgcaca  
29041 ttgtctcaa gtgcctctg attcttga atgtacgca ttggcatgga agtcacact  
29101 tgggaacat ggctgacta tcatggagc attaatgg atgacaaaga tccacaatt  
29161 aaagacaacg tcatctgt gaacaagc attgacgat acaaacatt cccaccaaca  
29221 gagcctaaa aggacaaaa gaaaagact gatgaagct agccttgc gcagagaca  
29281 aagaagcagc cactgtgac tcttctct cggctgaca tggatgatt ctcagaca  
29341 ctcaaaat ccatgagt agctctgt gattcaact aggcataac actcatgt  
29401 accacacaag gcagatggc tatgaaacg ttctgcaat tccgttacg atacatgt  
29461 tacttgtg cagaatgat tctgtaact aaacagcaca agtaggtta gtaactta  
29521 atctacata gcaatctta atcaatgtt aacattagg aggactgaa agagccacca  
29581 catttcatc gaggccagc ggagtacg cgagggtaca gtaataatg ctaggagag  
29641 ctgcctat ggagagccc taatgtgaa aataattt agtagtcta tcccatgt

29701 attttaatag ctcttagga gaatgacaaa aaaaaaaaaa aaaaaaaaaa a  
//



**Fig. 5. The Subgenomic HCV Replicon Used to Test  
The Efficacy of siRNA in Human Liver Cells**




Neo: neomycin phosphotransferase gene

Luc: fruit fly luciferase

EMCV: internal ribosome entry site taken from EMCV

NS3, NS4A, NS4B, NS5A, and NS5B: HCV nonstructural proteins

Fig. 6. The Effect of siRNA<sub>5</sub> on HCV Replication  
In Huh 5-2 Cells



**Fig. 7. Sequence Specificity Required for Mediating RNA Interference in Huh7 Cells**






Fig. 8. The Effect of siRNA5 of Cell Viability Measured by Cellular ATPase Activity




Fig. 9. The Effect of siRNA<sub>5</sub> on HCV Replication in Huh-7 Cells Measured by HCV RNA Assay




Fig. 10




Fig. 11




Fig. 12




Fig. 13





Fig. 14






Fig. 15






Fig. 16